National Clinical Guideline Centre

Pneumonia

Severity assessment tools

Clinical guideline <…>

Appendix G2

May 2014

Draft for consultation

Commissioned by the National Institute for Health and Care Excellence

Disclaimer
Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

Copyright
National Clinical Guideline Centre, 2014. Confidential.

Funding
National Institute for Health and Care Excellence

Contents

1 CAP 5

1.1 Severity assessment tools 6

1.1.1 Tools for assessing disease severity in people with LRTI in the community 6

1.1.2 Tools for assessing disease severity in people with CAP at first presentation 10

1.1.3 Validation studies ..... **Error! Bookmark not defined.**

2 References 105

1 CAP

1.1 Severity assessment tools

1.1.1 Tools for assessing disease severity in people with LRTI in the community

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures/ Results	Comments
Author and year: Francis 2012[22] **Study type:** prospective observational study in 14 primary care networks in 13 European countries with clinicians recording symptoms on presentation and management (part of Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe (GRACE) 01 study (www.grace-lrti.org) of acute cough) **Selection / patient setting**: Participating general practitioners were asked to recruit consecutive eligible patients in October and November 2006 and from	**Inclusion criteria:** Eligible patients were aged > 18 years who presented with an illness where an acute or worsened cough was the main or dominant symptom or the clinical presentation suggested an LRTI, with a duration of ≤ 28 days. **Exclusion criteria:** NR **All patients,** N: 3,368 participants had complete data **Exclusions due to**: incomplete data for CRB-65 **Included N:** 339 (12.6%) (complete data for CRB-65)	CRB-65	Mortality (0%) Hospitalization: 10/326 (3.1%) OR (95% CI) CRB-65 ≥ 1: 3.12 (0.16-60.24) CRB-65: 2.26 (0.21- 24.54) Interaction: 0.64 (0.02-18.41) Results from the multivariate analysis for the outcome of hospitalization for the sample of 326 patients with complete data *When the authors repeat the analysis with the whole sample (N = 2,545) with imputation of missing values they reported the OR (95%CI) for CRB-65 ≥ 1: 2.93 (0.77-11.17)	**Funding:** by the 6th Framework Programme of the European Commission (LSHM-CT-2005-518226), by the National Institute for Social Care and Health Research in Wales, and by the Research Foundation, Flanders (G.F0274.08N). **Limitations:** very low rate of complete data for CRB-65 (12.6%) **Additional**

	CRB-65			
	0	1		0
N (row %)	235 (69.3)	95 (28.0)	N (row %)	235 (69.3)
Age, mean (SD)	42.8 (12.4)	63.3 (15.3)	74.1 (7.5)	49.3 (16.5)
Prior duration of symptoms, median (IQR)	4 (3, 7)	5 (3, 8)	4 (3, 6)	5 (3, 7)
Baseline symptom severity score, mean (SD)	26.8 (6.0)	27.3 (6.2)	28.6 (6.9)	27.0 (6.1)

Reference	Patient Characteristics					Risk Assessment tools (including thresholds used)	Outcomes measures/ Results	Comments
late January to March 2007. (source: GRACE study) **Addressing missing data/non reliability of data**: Patients with missing data for any of these parameters were given a missing CRB-65 score. **Statistical analysis (including confounders adjusted for):** hierarchical logistic regression model and Cox proportional hazards modelling (with patients nested within clinicians), and controlling for antibiotic prescribing.	Antibiotics prescribed (column %)	165 (70.2)	70 (73.7)	7 (77.8)	242 (71.4)			**outcomes**: The authors also analysed the role of CRB-65 to predict prolonged moderately severe illness and time to recovery. None of these outcomes were significantly associated with elevated CRB-65 scores in the sample of patients with complete dataset. **Notes:**
	Duration of moderately bad symptoms in days, median (IQR)	6 (4, 9)	7 (4, 14)	7 (5, 14)	6 (4, 10)			
	Prolonged illness† (N = 334), N (%)	11 (4.8)	9 (9.5)	0 (0)	20 (6.0)			
	Hospitalisation (N = 326), N (%)	5 (2.2)	5 (5.5)	0 (0)	10 (3.1)			
	Day recovered, median (IQR)	12 (8, 21)	15 (10, 22)	19.5 (13, 22)	13 (8, 21)			

Reference	Patient characteristics	Risk assessment tools	Outcomes measured	Results	Comments
Author and year: Bont et al. 2008[10] **Study type:** Prospective, validation study using the derivation cohort from Lim et al. (hospital setting) **Selection/patient setting:** Patients with CXR-confirmed or suspected CAP presenting to primary care in The Netherlands **Addressing missing data/non**	**Diagnosis:** CXR-confirmed or suspected CAP **Inclusion criteria:** presence of new localizing signs on chest examination or new infiltrates on CXR, or when the GP had a strong suspicion of the patient having CAP because of severe dyspnoea in a very ill patient (even without chest signs) **Exclusion criteria:** patients with lung cancer, haematologic malignant neoplasm, HIV-infection, use of immunosuppressive medication, hospitalised during the 2 weeks preceding diagnosis, or nursing home residents **All patients:**	CRB-65: Low risk 0 Intermediate risk 1 or 2 High risk ≥ 3	30-day mortality 30-day hospitalisation	30-day mortality, n (%): 11 (3.5) 30-day hospitalisation, n (%): 47 (15)	**Funding:** Personal grant by The Netherlands Scientific Organisation to Dr Bont

CRB-65	**30-day mortality in original data by Lim et al. n (%)**	**30-day mortality in present study, n (%)**
0	2 (0.9)	0
1	18 (5.2)	2 (0.9)
2	30 (11.8)	5 (8.2)
3	36 (32.4)	4 (17.4)
4	3 (21.4)	0

Comparison of test characteristics of CRB-65 score ≥ 2 between the two studies

	Sensitivity (%)	**Specificity (%)**	**PPV (%)**	**NPV (%)**
Lim et al. study	76.8	64.3	18.6	96.3
Present study	82.2	75.2	10.7	99.1

Limitations: Mortality rates are low in primary care, therefore new studies may need to investigate less severe outcomes

Additional outcomes: Mortality according to hospital referral

Notes: "CRB-65 identifies low-risk patients in an elderly population in primary care and suggests

Reference	Patient characteristics	Risk assessment tools	Outcomes measured	Results	Comments
reliability of data: **Statistical analysis (including confounders adjusted for):** ROC analysis (validation study)	N: 315 Exclusion reasons: NR				that age alone is not a sufficient reason to classify patients as high risk”
	Included: N: 315				
	Age, mean: 77.3 **Age ≥ 65:** 100%				
	Gender: male, n (%): 145 (46)				
	Nursing home patients: excluded				
	Pneumonia severity, n (%): CRB-65 0: 0 CRB-65 1: 230 (73.2) CRB-65 2: 61 (19.4) CRB-65 3: 23 (7.3) CRB-65 4: 0				

1.1.2 Tools for assessing disease severity in people with CAP at first presentation

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Buising et al. 2006[12] **Study type:** Prospective **Selection / patient setting:** Tertiary teaching hospital in Melbourne. Adults admitted to hospital with a diagnosis of CAP **Addressing missing data/non reliability of data:** Data missing for 20 patients who	**Diagnosis:** CAP diagnosis was based on clinical assessment, initial pathology results, and CXR assessment by the clinician **Inclusion criteria:** Adults with a diagnosis of CAP **Exclusion criteria:** Aged < 18 years HAP (admitted to hospital for more than 48 hours within 2 weeks prior to presentation) Immunosuppression **All patients,** N: 392 Exclusions reasons: NR **Included** N: 392 **Age, median (range):** 74 (18-96)	• PSI • CURB • CURB-65 • revised ATS (2001): one of the 2 major criteria or 2 of 3 minor criteria • modified BTS (2001): the 4 CURB variables are assessed and if a patient has ≥ 2 variables they are classed as severe	• Mortality • ICU admission	a) Mortality , n (%); 37 (9.4) b) ICU admission, n (%): 26 (6.6) c) Predictive value of severity tools for mortality	**Funding:** National health and medical research council of Australia **Limitations** • 45 patients did not have a discharge diagnosis of pneumonia despite initial diagnosis, but authors support the inclusion of this group in the evaluation as it reflects the real-life context in which these tools will be used **Additional outcomes**: **Notes:** Mortality time point not

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results						Comments
had no blood tests performed. **Statistical analysis (including confounders adjusted for):** ROC analysis	**Gender: male, n (%):** 324 (59.7) **Nursing home patients, n (%):** 55 (14) **Comorbidities > 10%, n (%):** • Neoplastic disease: 54 (13.7) • Congestive heart failure: 80 (20.4) • Cerebrovascular disease: 74 (18.8) • Chronic renal failure: 47 (11.9) • COPD: 92 (23.4) • Dementia/neurological disease: 52 (13.2) • Diabetes: 87 (22.1) **Pneumonia severity**									specified
	Severity tool	**Patients, n (%)**		**Severity tool**	**Sensitivity % (95% CI)**	**Specificity % (95% CI)**	**PPV % (95% CI)**	**NPV % (95% CI)**	**ROC (95% CI)**	
	PSI			PSI V	67.5 (50.2-81.9)	82.1 (77.6-85.9)	28.4 (19.3-39.0)	96.0 (93.1-97.9)	0.82 (0.76-0.87)	
	I	346 (27.9)		PSI IV+V	97.3 (85.8-99.9)	47.9 (42.5-53.2)	16.4 (11.7-22.0)	99.4 (96.7-99.9)	0.82 (0.76-0.87)	
	II	325 (26.2)		CURB (≥2)	89.2 (74.5-	58.1 (52.7-	18.3 (12.9-	98.1 (95.1-	0.82 (0.75-	

Reference	Patient Characteristics		Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results						Comments
						96.9)	63.3)	24.7)	99.4)	0.88)	
	III	241 (19.4)			CURB-65 (≥ 3)	81 (64.8-92.0)	67.9 (62.7-72.7)	20.8 (14.5-28.4)	97.2 (94.2-98.8)	0.82 (0.76-0.88)	
	IV	165 (13.3)			Revised ATS	40.5 (24.7-57.9)	84.6 (80.4-88.2)	21.7 (12.7-33.3)	93.1 (89.7-95.6)	0.63 (0.54-0.71)	
	V	97 (7.8)			**Severity tool**	**Sensitivity % (95% CI)**	**Specificity % (95% CI)**	**PPV % (95% CI)**	**NPV % (95% CI)**	**ROC (95% CI)**	
	Revised ATS severe	70 (17.8)			PSI V	67.5 (50.2-81.9)	82.1 (77.6-85.9)	28.4 (19.3-39.0)	96.0 (93.1-97.9)	0.82 (0.76-0.87)	
	CURB severe	182 (46.4)			PSI IV+V	97.3 (85.8-99.9)	47.9 (42.5-53.2)	16.4 (11.7-22.0)	99.4 (96.7-99.9)	0.82 (0.76-0.87)	
	CURB-65 severe (3)	161 (41.0)			d) Predictive value of severity tools for ICU admission						
	LOS, median (range): 4 (1-76) days				**Severity tool**	**Sensitivity % (95% CI)**	**Specificity % (95% CI)**	**PPV % (95% CI)**	**NPV % (95% CI)**	**ROC (95% CI)**	
					PSI V	48 (27.8-68.7)	79 (74.5-83.1)	13.6 (7.2-22.6)	95.6 (92.7-97.6)	0.69 (0.59-0.77)	
					PSI IV+V	84 (63.9-95.4)	45.4 (40.2-50.7)	9.6 (6.0-14.3)	97.6 (94.0-99.3)	0.69 (0.59-0.77)	
					CURB (≥ 2)	84 (63.9-95.4)	56.2 (50.9-61.3)	11.7 (7.3-17.2)	98.1 (95.1-99.4)	0.76 (0.68-0.84)	
					CURB-65 (≥ 3)	57.7 (36.9-76.6)	64.7 (59.6-69.6)	10.4 (5.9-16.6)	95.5 (92.2-97.7)	0.66 (0.56-0.76)	
					Revised ATS	92 (73.9-99.0)	87.3 (83.4-90.5)	33.3 (22.4-45.7)	99.3 (97.7-99.4)	0.90 (0.81-0.94)	
					Modified BTS	96.0 (79.6-99.9)	48.7 (43.5-54.0)	11.4 (7.4-16.5)	99.4 (96.9-99.9)	0.72 (0.67-0.76)	

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Phua et al. 2009[36] **Study type:** Retrospective **Selection / patient setting:** University hospital in Singapore. Adults admitted to hospital with a diagnosis of CAP **Addressing missing data/non reliability of data:** **Statistical**	**Diagnosis:** CAP was defined as an acute infection of the pulmonary parenchyma associated with infiltrates on CXR and two or more clinical symptoms consistent with pneumonia (new cough or change in colour of respiratory secretions, dyspnoea, fever, hypothermia, rigors, and/or chest discomfort) **Inclusion criteria:** Adults with a diagnosis of CAP **Exclusion criteria:** • Hospitalised within 14 days of the onset of symptoms or discharged from the emergency department • Immunocompromised • Patients subsequently diagnosed with tuberculosis • Patients who fulfilled any IDSA/ATS major criteria for severe CAP on presentation **All patients,** N: 1310 Exclusions reasons: 68 fulfilled IDSA/ATS major criteria for severe	• PSI • IDSA/ATS minor criteria • CURB-65 High-risk patients were defined as having IDSA/ATS minor criteria ≥ 3, PSI IV or V, and CURB-65 ≥ 3	In hospital mortality	a) Hospital mortality n (%): 183 (14.7) b) AUC (95% CI) predicting in hospital mortality: • PSI: 0.86 (0.83-0.88) • CURB-65: 0.82 (0.78-0.85) • IDSA/ATS minor criteria: 0.88 (0.86-0.91) c) Number of deaths according to IDSA/ATS number of criteria:	**Funding:** None **Limitations:** • Data collection performed using medical records • Hospital mortality was higher than other studies, which might be due to different forms of mortality used. In this study, in-hospital mortality was chosen

Number of criteria	Number of deaths, n (%)
0	3 (0.9)
1	5 (1.5)
2	26 (10.8)
3	58 (35.2)
4	41 (42.3)
5	29 (61.7)
6	19 (100.0)
7	2 (100.0)

d) Prediction of hospital mortality by severity tool

Severity tool	ROC (95% CI)	Sensitivity %	Specificity %	PPV %	NPV %
IDSA/ATS minor criteria					
≥ 1	0.65 (0.62-0.69)	98.4	32.4	20.1	99.1
≥ 2	0.79 (0.76-0.82)	95.6	62.6	30.6	98.8
≥ 3	0.82 (0.79-0.86)	81.4	82.9	45.2	96.3
≥ 4	0.71 (0.67-0.76)	49.7	93	55.2	91.5
≥ 5	0.63 (0.58-0.68)	27.3	98.3	73.5	88.7
≥ 6	0.56 (0.51-0.61)	11.5	100	100	86.7

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
analysis (including confounders adjusted for): ROC analysis Chi test and Student *t* test	CAP **Included** N: 1242 **Age, mean (SD):** 65.7 (20.1) **Age ≥ 65 years, n (%):** 759 (61.1) **Gender: male, n (%):** 761 (61.3) **Nursing home patients, n (%):** 153 (12.3) **Comorbidities, n (%):** Neoplastic disease: 81 (6.5) Heart failure: 201 (16.2) Cerebrovascular disease: 341 (27.5) Renal disease: 131 (10.5) **Pneumonia severity according to number of IDSA/ATS minor criteria** **Number of criteria** / **Patients, n (%)**: 0: 346 (27.9) 1: 325 (26.2) 2: 241 (19.4) 3: 165 (13.3) 4: 97 (7.8) 5: 47 (3.8) 6: 19 (1.5) 7: 2 (0.2) **LOS, mean (SD):**			7: 0.51 (0.46-0.55); 1.1; 100; 100; 85.4 **PSI class** ≥ II: 0.59 (0.55-0.63); 100; 17; 17.2; 100 ≥ III: 0.68 (0.64-0.71); 99.5; 36.2; 21.2; 99.7 ≥ IV: 0.77 (0.74-0.80); 96.2; 57.9; 28.3; 98.9 V: 0.77 (0.73-0.82); 68.3; 86.6; 46.8; 94.1 **CURB-65** ≥ 1: 0.63 (0.59-0.67); 97.8; 28.4; 19.1; 98.7 ≥ 2: 0.74 (0.71-0.78); 89.1; 59.2; 27.4; 96.9 ≥ 3: 0.72 (0.68-0.77); 61.2; 83.3; 38.8; 92.5 ≥ 4: 0.62 (0.57-0.67); 27.3; 93.7; 58.8; 88.5 5: 0.53 (0.49-0.58); 6.6; 100; 100; 86.1	as outcome instead of 30-day mortality • Further research comparing IDSA/ATS with new predictions rules such as SMART-COP and SCAP will be needed **Additional outcomes**: Table 2 reports mortality RR for each individual IDSA/ATS criteria **Notes:** In-hospital mortality-

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
					time period not reported
				e) Relative risk (RR) of hospital mortality by severity tool	

Severity tool	RR (95% CI)
IDSA/ATS minor criteria	
≥ 1	23.17 (7.45-72.03)
≥ 2	25.71 (12.77-51.75)
≥ 3	12.11 (8.53-17.20)
≥ 4	6.46 (5.08-8.20)
≥ 5	6.49 (5.24-8.04)
≥ 6	7.54 (6.53-8.70)
7	6.85 (5.99-7.84)
PSI class	
≥ II	NA*
≥ III	81.46 (11.46-579.23)
≥ IV	25.06 (11.87-52.91)
V	7.87 (5.95-10.42)
CURB-65	
≥ 1	14.57 (5.45-38.91)
≥ 2	8.86 (5.65-13.91)
≥ 3	5.20 (3.98-6.79)
≥ 4	5.12 (4.03-6.50)
5	7.19 (6.26-8.27)

*NA due to NPV of 100%

The logistic regression model adjusted for delay to ICU admission and

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
				included number of PSI points (as it incorporates patient demographics, chronic conditions and acute parameters).	

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures/ Results	Comments

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures/ Results	Comments
Author and year: Kim et al, 2013[27] **Study type:** prospective multicentre study in 14 hospitals (13 were teaching centers and 1 was a secondary hospital) in Korea **Selection / patient setting**: consecutive patients in the participating hospitals were selected. **Addressing missing data/non reliability of data**: none mentioned. **Statistical analysis (including confounders adjusted for):** Both outcomes were analysed using a chi-square test. No adjustment for confounders was performed.	**Inclusion criteria:** Eligible patients were aged >18 years who presented with CAP (defined as shadowing on an admission chest radiograph or computed tomography in 48 h after admission and showing new infiltration or consolidation or pleural effusion consistent with pneumonia. **Exclusion criteria:** hospital acquired pneumonia, hospitalization over 72 hours in previous 14 days, patients with tuberculosis, secondary pneumonia, conditions likely to cause diagnostic confusion or where chest radiograph changes were equivocal, immunocompromised patients, neutropenia, leukemia, lymphoma, HIV infection, and splenectomy. **All patients,** N: 883 (882 were inpatients) **Exclusions due to**: none **Included N:** 883	PSI CURB-65	30-day mortality: 40/883 (4.5%_ ICU admission: 9.1%	**Funding:** By a grant from the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (A102065). **Limitations:** Almost all the participants in the study were inpatients/ multicentre study **Additional outcomes**: The authors also analysed the causes of death and compared their results to those of derivation studies. **Notes:**

	Sample (N=883)
- Age<50 years - Female - Nursing home resident	-20.5% - 40.7% - 1.1%
Coexisting medical conditions - Congestive heart failure - Cerebrovascular diseas - Neoplastic disease - Renal disease - Liver disease	-6% -9.2% - 8.2% - 3.3% - 3.1%

PSI	30-day mortality (n, %)	ICU admission (n, %)
I (≤50) (n=174)	4 (2.3%)	9 (5.2%)
II (51-70) (n=182)	5 (2.7%)	5 (2.7%)
III (71-90) (n=213)	5 (2.3%)	9 (4.2%)
IV (91-130) (n=245)	11 (4.5%)	29 (11.8%)
V (>130) (n=69)	14 (21.7%)	28 (40.6%)

CURB-65	30-day mortality (n, %)	ICU admission (n, %)
0 (n=260)	6 (2.3%)	11 (4.2%)
1 (n=300)	12 (4%)	17 (5.7%)
2 (n=216)	13 (6%)	23 (10.6%)
3 (n=88)	5 (5.7%)	17 (19.3%)
4 (n=17)	4 (23.5%)	10 (58.8%)
5 (n=2)	0	2 (100%)

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Jeong et al. 2011[25] **Study type:** Retrospective **Selection / patient setting:** Emergency department of a tertiary hospital in Korea. Adults admitted to hospital with a diagnosis of CAP **Addressing missing data/non reliability of data:**	**Diagnosis:** Acute illness with clinical features of pneumonia and infiltrates on CXR **Inclusion criteria:** Adults with a diagnosis of CAP **Exclusion criteria:** • Hospital-acquired pneumonia • Transfer from other hospitals prior to admission • Recent administration of antibiotics • Presence of aspiration tendency • Patients who left the hospital against medical advice • Presence of other infectious diseases • If a patient was admitted more than once during a 6-month period, only the first hospitalisation was included **All patients,** N: 526 **Included** N: 502 **Age, mean years (SD):** survival group – 67.58 (15.83), non-survivors – 77.03 (8.84) **Gender: male, n (%):** survival	• PSI • CURB-65 • APACHE II	30-day mortality	a) 30-day mortality n (%): 61 (12.15) b) AUC (95% CI) predicting 30-day mortality: • PSI: 0.795 (0.742 to 0.848) • CURB65: 0.764 (0.703 to 0.825) • APACHE II: 0.847 (0.804 to 0.890) c) 30-day mortality **PSI criteria** / **30-day mortality, n (%)** I: 0 (0) II: 1 (1.6) III: 9 (14.8) IV: 24 (39.3) V: 27 (44.3) **CURB65** / **30-day mortality, n (%)** 0: 1 (1.6) 1: 10 (16.4) 2: 21 (34.4) 3: 17 (27.9) 4: 11 (18.0) 5: 1 (1.6)	**Funding:** NR **Limitations:** • Retrospective design • Conducted at a single hospital **Additional outcomes**: **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Statistical analysis (including confounders adjusted for): ROC analysis	group – 254 (57.6), non-survivors – 43 (70.5) **Nursing home patients, n (%):** NR **Comorbidities >10%, n (%):** Neoplastic disease: 71 (14) Cerebrovascular: 83 (16.5) Diabetes: 122 (24.3) Hypertension: 184 (36.6) Tuberculosis: 72 (14.3) Asthma and COPD: 73 (14.5) **Pneumonia severity according to PSI and CURB65 criteria** **PSI criteria** – **Patients, n** I – 43 II – 79 III – 125 IV – 173 V – 82 **CURB65** – **Patients, n** 0 – 92 1 – 174 2 – 141 3 – 73 4 – 21 5 – 2				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	APACHE II, mean (SD): survival group 10.88 (5.49), non-survivors 19.33 (6.33) **LOS, mean (SD):** NR				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Bello et al. 2012[9] **Study type:** Prospective **Selection / patient setting:** Consecutive patients admitted to the emergency department of a University hospital in Spain. Adults admitted to hospital with a diagnosis of CAP **Addressing missing**	**Diagnosis:** Acute illness with symptoms of LRTI and new infiltrate on CXR **Inclusion criteria:** Adults with a diagnosis of CAP **Exclusion criteria:** Severe immunosuppression or patients having immunosuppressive therapy, leucopenia or neutropenia and/or chemotherapy in the previous year, pulmonary abscess, aspiration pneumonia and obstructive pneumonia, possible or known active neoplasia **All patients,** N: 260 **Included** N: 228 **Age, median years (SD):** 73 (60 - 80) **Gender: male, n (%):** 139 (61) **Nursing home patients, n (%):** NR **Comorbidities > 10%, n (%):** • Not-active neoplasia: 30 (13.2) • Heart disease: 84 (36.8) • Cerebrovascular disease: 47 (20.6) • COPD: 72 (31.6) • Renal disease: 35 (15.4) • Chronic renal disease: 27 (11.8) • Diabetes: 44 (19.3)	• PSI • CURB-65	• 30-day mortality	a) 30-day mortality n (%): 13/224 (5.8) b) AUC (95% CI) for predicting 30-day mortality: • PSI: 0.858 (0.805 – 0.901) • CURB65: 0.851 (0.798 – 0.895)	**Funding:** Grant from the Aragon respiratory apparatus society (SADAR) **Limitations:** • Study focused on the role of proadrenomedullin to predict mortality • Single hospital **Additional outcomes**: **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
data/non reliability of data: **Statistical analysis (including confounders adjusted for):** ROC analysis	**Pneumonia severity according to PSI and CURB65 criteria** **PSI criteria** / **Patients, n (%)** I: 19 (8.3) II: 30 (13.2) III: 40 (17.5) IV: 85 (37.3) V: 54 (23.7) **CURB65** / **Patients, n (%)** 0: 33 (14.5) 1: 60 (26.3) 2: 86 (37.7) 3: 32 (14.0) 4: 12 (5.3) 5: 5 (2.2) **LOS, mean (SD):** NR				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Kontou et al. 2009[29] **Study type:** Retrospective **Selection / patient setting:** Private teaching hospital in Hartford, USA. Adults admitted to hospital with a diagnosis of CAP caused by S pneumoniae **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):**	**Diagnosis:** CAP was diagnosed based on clinical signs and symptoms, including new infiltrate on CXR, and at least one sputum culture or 2 blood cultures positive for *S. pneumoniae* **Inclusion criteria: [from previous study, Sun2006]** Adults (≥ 18 years) with a diagnosis of CAP caused by *S. pneumonia*. Patients were included if they were ≥ 18 years old; had at least one sputum culture or two blood cultures positive for *S. pneumoniae*; and had signs and symptoms consistent with the diagnosis of CAP including the presence of a new infiltrate on chest radiograph and at least two of the following within 1 day of the first positive culture: fever or hypothermia; WBC count > 10,000/µL or > 15% bands or leukopenia (WBC < 4,500/µL); auscultatory findings on pulmonary examination and/or evidence of pulmonary consolidation; new cough with or without sputum production; new-onset dyspnoea or tachypnoea; or hypoxemia with a Po2 < 60mm Hg	• PSI • IDSA/ATS 2007: ≥ 1 of 2 major criteria, and ≥ 3 of 9 minor criteria • ATS 2001: ≥ 1 of 2 major criteria, and ≥ 2 of 3 minor criteria • CURB: ≥ 2 of 4 criteria	Mortality	a) Mortality, n (%): 20 (12.6) b) ICU admission, n (%): 31 (19.6) c) Multivariable regression model to identify variables independently associated with mortality; OR (95% CI, p) • PSI V: 3.76 (1.31-10.82, p = 0.014) The multivariate model included all variables with p>0.2 in the univariate analysis: - OR for mortality: PSI V and mechanical ventilation - OR for ICU admission: tachypnoea, confusion, PaO2/FiO2 ratio≤250, hypotension *d)* Predictive value of different tools for mortality **Severity tool** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** IDSA/ATS: 75 / 65 / 24 / 95 ATS: 65 / 71 / 25 / 93 PSI IV+V: 95 / 49 / 21 / 99 PSI V: 50 / 82 / 29 / 92 CURB (≥ 2): 50 / 75 / 22 / 91 e) Predictive value of different tools for ICU admission **Severity tool** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** IDSA/ATS: 90 / 72 / 44 / 97 ATS: 90 / 80 / 53 / 97	**Funding:** None **Limitations** • Retrospective design; however, all data to assess each criteria were available or calculated from the ED admission log • 26 patients were admitted from a nursing home, which represents a HCAP population; however, as all cases had confirmed pneumococcal pneumonia, these patients are no different from CAP (aetiology is the

X^2 test, *t* test or Mann-Whitney test	on room air **Exclusion criteria: [from previous study, Sun2006]** Patients were excluded if their total hospitalization was < 2 days, if they were immunocompromised, had known or suspected tuberculosis, known or suspected Pneumocystis jiroveci, or concomitant pneumonia or other infection at baseline caused by viruses, fungi, or other bacteria except intracellular pathogens **All patients,** N: 158 Exclusions reasons: NR **Included** N: 158 **Age, mean (SD):** 63.1 (18.9) **Gender: male, n (%):** 80 (50.6) **ursing home patients, n (%):** 26 (16.5) **Comorbidities > 10%, n (%):** • Diabetes: 34 (21.5) • COPD: 43 (27.2) • Neoplastic disease: 17 (10.8) • Heart failure: 22 (13.9) **Pneumonia severity:** **PSI class** / **Patients, n (%)** I: 11 (7) II: 21 (13.3) III: 37 (23.4) IV: 54 (34.2) V: 35 (22.1) **LOS, mean (SD):** 8.8 (8)			PSI IV+V	81	50	28	91	main differentiation between these populations) **Additional outcomes**: **Notes:** Mortality- time period not reported Only PSI V and mechanical ventilation were independently associated with mortality (r^2 = 0.240). Non-significant variables were removed from the final model
				PSI V	45	83	40	90	
				CURB (≥ 2)	58	79	40	89	

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Chang et al. 2013[17] **Study type:** Prospective **Selection / patient setting:** Two large hospitals in New Zealand. Adults admitted to hospital with a diagnosis of CAP **Addressing missing data/non reliability of data:** **Statistical analysis**	**Diagnosis:** Acute illness with clinical features of pneumonia and infiltrates on CXR **Inclusion criteria:** Adults with a diagnosis of CAP **Exclusion criteria:** • Pneumonia was not the main reason for admission • Pneumonia was associated with bronchial obstruction, bronchiectasis, or tuberculosis • Severely immunocompromised with neutropenia, HIV infection or currently receiving cancer chemotherapy • Hospitalised within the previous 14 days or transferred from a long term hospital-level care facility **All patients,** N: 474 **Included** N: 453 **Age ≥ 65 years, n (%):** 264 (58) **Gender: male, n (%):** 233 (51) **Nursing home patients, n (%):** NR **Comorbidities >10%, n (%):** Chronic lung disease: 171 (37.7) Heart failure: 94 (20.7) Diabetes: 54 (12) Cerebrovascular disease: 52 (11.4)	• PSI • CURB-65	30-day mortality	b) 30-day mortality n (%): 26 (5.5) c) AUC (95% CI) predicting 30-day mortality: • PSI: 0.87 d) 30-day mortality	**Funding:** Health research council of New Zealand, Waikato respiratory research fund **Limitations:** Aim of the study was to study the role of NT-proBNP in predicting mortality **Additional outcomes**: **Notes:**

PSI criteria	30-day mortality, n
I	0
II	0
III	0
IV	7
V	19
CURB65	**30-day mortality, n**
0	0
1	0
2	10
3	8
4	5
5	1

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
(including confounders adjusted for): ROC analysis	**Pneumonia severity according to PSI and CURB65 criteria** **PSI criteria** / **Patients, n** I: 69 II: 65 III: 90 IV: 153 V: 77 **CURB65** / **Patients, n** 0: 79 1: 114 2: 122 3: 74 4: 23 5: 1 **LOS, mean (SD):** 6.7 days				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Ewig et al. 2004[20] **Study type:** Prospective **Selection / patient setting:** Tertiary care university hospital in Barcelona, Spain Consecutive patients admitted to hospital with a diagnosis of CAP **Addressing missing data/non reliability of data:** **Statistical analysis (including**	**Diagnosis:** CAP was diagnosed based on clinical signs and symptoms, and new infiltrate on CXR **Inclusion criteria:** Patients with a diagnosis of CAP **Exclusion criteria:** Severe immunosuppression Pneumonia as an expected terminal event of a severe chronic disabling comorbidity Alternative diagnosis during follow up **All patients,** N: 731 eligible Exclusions reasons: 14 patients who died of pneumonia as an expected terminal event of a severe chronic disabling comorbidity 21 patients with undocumented treatment **Included** N: 696 **Age, mean (SD):** 67.8 (17.1) **Aged > 65 years, n:** 464 **Gender: male, %:** 66	• PSI • CURB (modified BTS rule): respiratory rate ≥ 30/min, diastolic blood pressure ≤ 60 mmHg, confusion, blood urea nitrogen > 7 mmol/l • CRB (BTS rule II): respiratory rate ≥ 30/min, diastolic blood pressure ≤ 60 mmHg, confusion • modified ATS: at least 2 of the following 3 minor criteria (SBP < 90 mmHg, multilobar involvement, PaO_2/FiO_2 < 250) or 1 of the following 2 major criteria (requirement	Mortality ICU admission	a) Number of patients admitted to ICU, death by PSI class **PSI class** / **ICU admission, n (%)** / **Mortality, n (%)** I: 0 / 0 II: 5 (10) / 1 (2) III: 10 (10) / 3 (3) IV: 40 (21) / 15 (8) V: 35 (31) / 20 (18) b) Number of patients admitted to ICU, death by CURB **CURB** / **ICU admission, n (%)** / **Mortality, n (%)** 0: 7 (3) / 3 (1) 1: 44 (19) / 17(7) 2: 24 (26) / 7 (8) 3: 20 (61) / 13 (39) 4: 3 (38) / 1 (13) c) AUC (95% CI) predicting ICU admission: • PSI: 0.607 (0.607-0.727) • CURB: 0.732 (0.676-0.787) [All other predictive rules were not suitable for this analysis] *d)* Predictive value of different tools for mortality **Severity tool** / **Sensitivity % (95% CI)** / **Specificity % (95% CI)** / **PPV % (95% CI)** / **NPV % (95% CI)** Modified ATS: 94 (82.5-98.7) / 93 (90.6-94.7) / 49 (38.2-59.7) / 99.5 (90.8-	**Funding:** Red Gira ISCIII-03/063 and Red Respira ISCIII-RTIC-03/11 and FISS PI020616 **Limitations** NR **Additional outcomes**: **Notes:** Mortality-time period not reported "Our data do not support the use of a cut off of ≥2 CURB criteria for deciding whether to admit to ICU. "We didn't find clear cut

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
confounders adjusted for): ROC analysis	**Nursing home patients:** NR **Comorbidities:** NR **Pneumonia severity** **PSI was calculated in 489 patients** **PSI class** / **Patients, n (%)** I: 34 (7) II: 50 (10) III: 98 (20) IV: 194 (40) V: 113 (23) **CURB was calculated in 592 patients** **CURB** / **Patients, n (%)** 0: 229 (39) 1: 231 (39) 2: 91 (15) 3: 33 (6) 4: 8 (1) **LOS, mean (SD):** 8.8 (8)	for mechanical ventilation or septic shock) • alternative ATS: 2 of 6 minor criteria or 1 of 4 major criteria		94.7) CRB (BTS II): 53 (38.1-67.9); 83 (80.3-86.2); 19 (12.6-26.7); 96 (94.1-97.5) CURB (modified BTS): 51 (35.1-67.1); 80 (76.3-83.1); 16 (10.1-23.3); 96 (93.4-97.3) *e)* Predictive value of different tools for ICU admission **Severity tool** / **Sensitivity % (95% CI)** / **Specificity % (95% CI)** / **PPV % (95% CI)** / **NPV % (95% CI)** Modified ATS: 69 (59.7-77.2); 98 (96.4-98.9); 87 (78.3-93.1); 94 (91.8-95.8) Alternative ATS: 87 (79.2-92.5); 82 (79.0-95.4); 49 (42.1-56.4); 97 (95.0-98.3) CRB (BTS II): 44 (5.1-53.9); 86 (82.7-88.6); 38 (30.1-47.2); 89 (85.6-91.1) CURB (modified BTS): 48 (37.8-58.3); 83 (79.2-86.0); 36 (27.5-44.4); 89 (85.7-91.6)	offs for mortality risk between CURB classes 1 and 2 and CURB 3 and 4”

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Liapikou et al. 2009[31] **Study type:** Prospective **Selection / patient setting:** Tertiary care university hospital in Barcelona, Spain. Consecutive patients aged>15 years admitted to the ED with a diagnosis of CAP **Addressing missing data/non reliability of data:** **Statistical**	**Diagnosis:** Pneumonia was defined as a new infiltrate on CXR, and clinical signs and symptoms of LRTI **Inclusion criteria:** Patients aged >15 years with a diagnosis of CAP **Exclusion criteria:** Immunosuppression **All patients,** N: 2102 eligible Exclusions reasons: NR **Included** N: 2102 **Age, mean (SD):** • ICU patients: 64 (17) • Non-ICU patients: 67 (18) **Gender: male, n (%):** • ICU patients: 144 (61.28) • Non-ICU patients: 1147 (61.44) **Nursing home patients:** NR **Comorbidities > 10%:**	• PSI • CURB-65 • IDSA/ATS **IDSA/ATS definition of severe CAP:** patients who met at least 1 of 2 major severity criteria or 3 of 9 minor severity criteria	30-day in-hospital mortality ICU admission	a) ICU admission, n (%): 235 (11.18) b) Mortality at 30 days: 109 (5.19) c) IDSA/ATS criteria for severe CAP predictive value for ICU admission **Severe CAP IDSA/ATS criteria** **Sensitivity %**: 71 **Specificity %**: 88 **Positive likelihood ratio**: 5.77 **Negative likelihood ratio**: 0.33 **Univariate RR (95% CI)**: 17.5 (12.8-23.9) d) Univariate association of severity tools with 30-day in-hospital mortality **Severity tool** / **RR (95% CI** Severe CAP IDSA/ATS: 6.8 (4.6-10.1) PSI: 1.62 (1.35-1.95) CURB-65: 2.48 (2.06-2.98) e) The sensitivity and specificity	**Funding:** CibeRes (CB06/06/0028). 2005 Suport als Grups de Recerca 00822, European Respiratory Society Fellowship (AL), Institut d'investigacions Biomediques August Pi I Sunyer **Limitations** • Blood urea nitrogen level was not systematically determined, so serum creatinine level was used as a surrogate • DNI (do not intubate) decisions were only available for 41% of cases, previous DNI orders may influence the decision for ICU admission • Variability of clinician's judgement and constraints on the

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
analysis (including confounders adjusted for): X^2 or Fisher's exact test Unpaired t test	**Comorbidities** / **ICU patients** / **Non-ICU patients** Chronic heart failure: 41 (18) / 372 (20) Chronic pulmonary disease: 109 (47) / 834 (45) Diabetes: 48 (21) / 352 (19) Neurological disease: 45 (19) / 359 (19) **Pneumonia severity, mean (SD)** **Severity tool** / **ICU patients** / **Non-ICU patients** PSI: 120 (38) / 97 (40) CURB-65: 1.8 (1.0) / 1.2 (1.0) **LOS, mean days (SD)** • ICU patients: 7.1 (6.5) • Non-ICU patients: 18.0 (14.8)			of severe CAP IDSA/ATS criteria to predict hospital mortality were 58% and 88%, respectively.	availability of ICU beds may have influenced decisions on ICU admission **Additional outcomes**: Predictive values for each minor and major criteria **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Feldman et al. 2009[21] **Study type:** Prospective **Selection / patient setting:** 21 hospitals across 10 countries. Patients diagnosed with bacteraemic pneumococcal pneumonia **Addressing missing data/non reliability of data:** The analysis included 739 patients for whom missing laboratory parameters were considered as normal values. A separate analysis was conducted in 519 patients, excluding	**Diagnosis:** Pneumonia confirmed by CXR associated with pneumococcal bacteraemia **Inclusion criteria:** Patients with a diagnosis of bacteraemic pneumococcal pneumonia **Exclusion criteria:** Patients who also had meningitis (59), endocarditis (7), those with uncertain ICU status (9), and those without evaluation of their mental status (3) **All patients,** N: 844 Exclusions reasons: see exclusion criteria above **Included** N: 766 **Age, mean (SD):** NR **Gender: male, %:** NR **Nursing home patients:** NR	• modified ATS: 2 minor or 1 major criteria • IDSA/ATS: any major or 3 minor • CURB-65: ≥ 3 • CRB 65: ≥ 3 • PSI IV or V	14 day mortality	a) Predictive values for 14 day mortality: **Severity tool** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** Modified ATS: 72.6 / 80.2 / 38.1 / 94.6 IDSA/ATS: 79.2 / 66.0 / 28.1 / 95.0 CURB-65 (≥ 3): 52.8 / 80.1 / 30.8 / 91.0 PSI IV or V: 80.2 / 55.6 / 23.2 / 94.4 b) ROC for 14 days mortality: • modified ATS: 0.7361 • IDSA/ATS: 0.7099 • CURB-65: 0.7365 • PSI: 0.721 c) 14-day mortality (%) by severity **Severity tool** / **Mortality % (n deaths/total)** Modified ATS: 27.5 (544/766) IDSA/ATS: 40.6 (311/766) CURB-65 (≥ 3): 24.6 (183/744) CRB-65 (≥ 3): 9.9 (74/744) PSI IV or V: 49.5 (367/742)	**Funding:** NR **Limitations:** The study population was restricted to patients with pneumococcal bacteraemia, but it was not specified whether patients had CAP. However, *S. pneumonia* is the most common cause of CAP, and the most common pathogen in cases of pneumonia admitted to ICU. **Additional**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
any patients with missing values for any of the severity tools **Statistical analysis (including confounders adjusted for):** ROC analysis	**Comorbidities:** NR				**outcomes:** **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Spindler et al. 2006[43] **Study type:** Prospective/retrospective **Selection / patient setting:** Karolinska University hospital in Sweden. Consecutive patients (86) with bacteraemic pneumococcal pneumonia, and retrospective review of hospital records of patients with bacteraemic pneumococcal pneumonia (28) **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP with positive blood cultures for S pneumoniae and infiltrates on CXR **Inclusion criteria:** Patients with CAP and invasive pneumococcal disease **Exclusion criteria:** Patients who had treatment in hospital within the previous 30 days of admission **All patients,** N: 114 Exclusions reasons: NR **Included** N: 114 **Age, mean (SD):** 57.1 (17.5) **Gender: male, n (%):** 62 (54.4) **Nursing home patients:** NR **Comorbidities > 10%, n (%):** • Chronic heart condition: 27 (23.7) • Chronic lung condition: 12 (8.4) • Cancer: 23 (20.2) • Immunosuppressive treatment: 17	• PSI (≥ IV) • CURB-65 (≥ 3) • modified ATS: > 1 minor or ≥ 1 major criteria	Mortality ICU admission	a) Mortality, n (%): 13 (11.4) b) Mortality AUC • PSI: 0.85 • CURB-65: 0.84 • modified ATS: 0.83 c) Predictive values for mortality **Severity tool** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** PSI IV-V: 100 / 60 / 25 / 100 CURB-65 (3-5): 62 / 86 / 36 / 95 Modified ATS (1 major > 1minor): 85 / 84 / 41 / 98 d) Predictive values for ICU admission **Severity tool** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** PSI IV-V: 95 / 64 / 36 / 98 CURB-65 (3-5): 71 / 87 / 55 / 91 Modified ATS (1 major > 1minor): 90 / 90 / 67 / 98	**Funding:** NR **Limitations** • The study was partly retrospective; however no difference was seen in the number of missing variables in the two patient groups • Time from admission to antibiotic initiation has an impact on mortality but such data were not available • Creatinine levels were used instead of urea levels **Additional outcomes**:

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	(14.9) **Pneumonia severity**				**Notes:**

PSI class	Patients, n (%)
I-II	47 (41.2)
III	14 (12.3)
IV	31 (37.2)
V	22 (19.3)
CURB-65	**Patients, n (%)**
0	42 (36.8)
1	27 (23.7)
2	23 (20.2)
3	17 (14.9)
4	4 (3.5)
5	1 (0.9)
mATS	**Patients, n (%)**
0	72 (63.2)
1 minor	15 (13.2)
>1 minor and/or ≥1 major	27 (23.7)

Reference	Patient Characteristics	Risk Assessment tools at hospital admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Angus et al. 2002[4] **Study type:** Prospective **Selection / patient setting:** Inpatients with CAP of the Pneumonia PORT cohort study at 3 US and one Canadian sites **Addressing missing data/non reliability of data:** NR **Statistical analysis (including confounders adjusted for):** • ROC analysis • Chi statistics of Fisher exact test for categorical variables • Student t test or Mantel-Cox log rank test for continuous variables	**Diagnosis:** CAP diagnosis was based on clinical and CXR evidence of pneumonia within 24 hours of presentation **Inclusion criteria:** Patients with CAP **Exclusion criteria:** NR **All patients,** N: 1339 Exclusions reasons: NR **Included** N: 1339 **Age, mean (SD):** NR **Gender: male, n (%):** NR **Nursing home patients, n (%):** 184 (13.74) **Comorbidities, n (%):** • Chronic pulmonary disease: 451 (33.68)	• PSI • original ATS: severe CAP is defined by the presence of 1 of 7 risk factors • revised ATS: severe CAP is defined by the presence of 2 of 3 minor criteria or 1 of 2 major criteria	• 30-day mortality • ICU admission	a) 30-day mortality, (%): Non-ICU (6.9), ICU (15.3) b) ICU admission, n (%): 170 (12.7) c) ATS and PSI prediction for 30-day mortality: **Severity tools** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** / **ROC (95% CI)** / **RR (95% CI)** ATS original / 79.8 / 41.4 / 8.8 / 96.6 / 0.60 (0.54-0.65) / 2.6 (1.5-4.5) ATS revised / 39.6 / 67.6 / 8.2 / 93.9 / 0.63 (0.57-0.69) / 1.3 (0.9-2.1) PSI IV or V / 94.4 / 53.2 / 12.6 / 99.3 / 0.75 (0.71-0.78) / 16.8 (6.8-41.8) d) ATS and PSI prediction for ICU admission: **Severity tools** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** / **ROC (95% CI)** / **RR (95% CI)** ATS original / 81.8 / 43.1 / 17.3 / 94.2 / 0.61 (0.57-0.65) / 3.0 (2.0-4.5) ATS revised / 70.7 / 72.4 / 26.4 / 94.7 / 0.68 (0.64-0.73) / 4.9 (3.4-7.1) PSI IV or V / 72.9 / 53.4 / 18.5 / 90.3 / 0.60 (0.56-0.65) / 2.7 (1.9-3.9)	**Funding:** Agency for Healthcare Policy and Research, National Institute of Medical Sciences, and unrestricted educational grant from Amgen **Limitations:** • Data from the cohort were collected in the early and mid 1990s, so care patters may not be representative of current care • There is no gold standard for the term

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	• Coronary artery disease: 349 (26.06) • Congestive heart failure: 225 (16.80) • Renal disease: 139 (10.38) • Dementia: 133 (9.93) **Pneumonia severity:** PSI class / Patients, n (%) I / 184 (13.7) II / 233 (17.4) III / 253 (18.9) IV / 446 (33.3) V / 223 (16.6) **LOS, median (range):** NR **DNR order, n (%):** 199 (14.8)				"severe CAP" and the definitions used are arbitrary **Additional outcomes**:

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Valencia et al. 2007[45] **Study type:** Prospective **Selection / patient setting:** One tertiary hospital in Barcelona, Spain. Consecutive patients with CAP and PSI-V (PSI ≥ 130) on admission **Addressing missing data/non reliability of data:** NR **Statistical analysis (including**	**Diagnosis:** CAP was defined as symptoms of lower respiratory tract infection plus new infiltrates seen on a CXR and the absence of an alternative diagnosis **Inclusion criteria:** Patients with CAP and PSI-V on admission **Exclusion criteria:** Patients with a hospital admission in the previous month or those who had received antibiotic IV treatment. Also, those patients receiving chemotherapy and inmunocompromised patients **All patients,** N: 457 Exclusions reasons: NR **Included** N: 457	• CURB • CURB-65 • modified ATS: includes 2 major criteria (mechanical ventilation and shock) or 2 of 3 minor criteria • PSI-V (acute PSI)	• Hospital mortality • ICU admission	a) Hospital mortality, n (%): 107 (23) b) ICU admission, n (%): 92 (20) c) Predictive value of severity tools for hospital mortality: **Severity tools** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** CURB: 72 / 42 / 24 / 86 Modified ATS: 72 / 77 / 44 / 91 CURB-65: 60 / 44 / 21 / 81 PSI-V: 80 / 57 / 32 / 92 d) Predictive value of severity tools for ICU admission: **Severity tools** / **Sensitivity %** / **Specificity %** / **PPV %** / **NPV %** CURB: 78 / 45 / 30 / 87 Modified ATS: 73 / 48 / 30 / 85 CURB-65: 75 / 80 / 53 / 91 PSI-V: 71 / 56 / 33 / 86	**Funding:** Fondo de Investigaciones Sanitarias grant 02/0632, and Institut de Investigacions Biomediques August Pi i Sunyer grant 2005 SGRQ/00822, and Centro de Investigacion Biomedica en Red-Enfermedades Respiratorias CB 06/06/0028. Dr Mauricio Valencia received a research fellowship grant in 2002 funded by the European Respiratory Society. **Limitations** • Despite the use of severity scores, ICU admission decisions are still based mainly on the clinical judgment of the attending physicians. • It is very possible that the study cohort includes some patients who would now be classified as having health-care-associated pneumonia (HCAP). The study was carried out before the definition of this category in the ATS consensus statement was published in 2005 **Additional outcomes**: **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
confounders adjusted for): ROC analysis	**Age, mean (SD):** 79 (11) **Gender: male, n (%):** 320 (70) **Nursing home patients, n (%):** 68 (14.8) **Comorbidities (>10%), n (%):** • Any pulmonary disease: 277 (60) • COPD: 181 (39.6) • Heart disease: 166 (36) • Neurologic disorder: 133 (29) • Chronic renal disease: 115 (25) • Diabetes: 70 (15.3) • Malignancy: 90 (19.7) **Pneumonia severity, mean (SD):** PSI: 154 (20) points **LOS, median (range):** NR				[A very significant proportion of hospitalized patients with CAP belong to PSI-V; while the mortality risk in this group was high, relatively few patients were admitted to the ICU because the PSI classification identified a very heterogeneous group of patients, many of whom did not have severe acute illness]

Reference	Patient Characteristics	Risk Assessment tools at ICU admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Belkhouja et al. 2012[8] **Study type:** Retrospective **Selection / patient setting:** One hospital in Tunisia. Consecutive patients with CAP admitted to the ICU with severe pneumoccocal pneumonia **Addressing missing data/non reliability of data:** NR **Statistical analysis (including**	**Diagnosis:** CAP was defined as acute symptoms of lower respiratory tract infection plus new infiltrates seen on a CXR at hospital admission **Inclusion criteria:** Patients with CAP positive for *S. pneumoniae* **Exclusion criteria:** Aged<15 years, severe immunosuppression **All patients,** N: 273 Exclusions reasons: Non pneumococcal pneumonia **Included** N: 132 **Age, mean (SD):** 49.5 (21.6) **Gender: male, n (%):** 109 (82.5)	• SOFA • CURB-65 • PSI	• ICU mortality	a) ICU mortality, n (%): 107 (23) a) Univariate analysis of continuous variables: **Severity score** / **Dead (median, range)** / **Alive (median, range)** / **p value** SOFA / 6 (1-14) / 2 (0-22) / < 0.001 CURB-65 / 3 (2-5) / 2 (0-5) / < 0.001 b) Univariate analysis of categorical variables: PSI ≥ IV: OR for mortality = 13.6 (95% CI 3.88-47.46, p < 0.001) c) Multivariate analysis of factors predicting ICU mortality: The need for mechanical ventilation at ICU admission, SOFA ≥ 4 and serum creatinine ≥ 102µmol/l were the only independent factors associated with mortality • SOFA ≥ 4: OR for mortality = 3.1 (95% CI 1.56-6.13, p = 0.001) [All the statistically significant variables in the univariate analysis were included in the multiple logistic regression analysis model with a stepwise forward selection: age, SAPSII, SOFA at admission, CURB-65, serum glucose at	**Funding:** NR **Limitations:** • Retrospective study • Study period is very wide (1999-2008) • Single centre study **Additional outcomes**: Simplified acute physiology score II (SAPSII), Glasgow coma score (GCS) Notes: Severe CAP

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
confounders adjusted for): • Categorical variables– chi squared test of Fisher's exact test • Continuous variables – Student's t test or Mann-Whitney U test	**Nursing home patients, n (%):** NR **Comorbidities, n (%):** • Any pulmonary disease: 67 (54.5) • COPD: 51 (38.6) • Heart disease: 27 (20.5) • Diabetes: 21 (16) **Pneumonia severity, mean (SD)/median (range):** • SOFA: 2 (0-22) •CURB-65: 2 (0-5) • PSI II and III: 60 (45.5) • PSI IV: 35 (26.5) • PSI V: 37 (28) **LOS in ICU, median (range):** 9.5 (1-68) days			admission, serum creatinine at admission, arterial pH at admission, PaO_2/FiO_2 at admission, PSI ≥ IV, heart disease, COPD, diabetes, bilateral pneumonia, multilobar pneumonia, septic shock at admission, acute lung injury/acute respiratory distress syndrome at admission, multiple organ failure at admission, mechanical ventilation required at admission]	

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Guo et al. 2012[24] **Study type:** Retrospective **Selection / patient setting:** One teaching hospital in China. Adults admitted to hospital with a diagnosis of CAP **Addressing missing data/non reliability of data:** NR **Statistical**	**Diagnosis:** CAP diagnosis was based on infiltrate on CXR and two or more clinical symptoms (fever, hypothermia, rigors, sweats, new cough or change in colour or respiratory secretions, dyspnoea) **Inclusion criteria:** All patients had CXR or CT scans. **Exclusion criteria:** Age < 18 years, hospitalised in the previous 28 days, HIV-related disorders, active tuberculosis, concurrent infectious disease, end – stage diseases, or patients with written DNR orders **All patients,** N: 1245 Exclusions reasons: NR **Included** N: 1230	• CURB-65 • IDSA/ATS minor criteria	Hospital mortality	a) Hospital mortality , n (%); 16 (1.3) b) Predictive value for hospital mortality by CURB-65 and IDSA/ATS minor criteria	**Funding:** Medical science and technology foundation of Guandong province in 2010, the planned science and technology project of Shenzhen municipality in 2011, and the non-profit scientific research project of Futian district in 2011 **Limitations** • Retrospective single-centre study **Additional outcomes**: [The number of

Severity	Mortality, n (%)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
CURB-65					
CURB-65 ≥ 0	0 (0)	100	0	1.3	0
CURB-65 ≥ 1	4 (1)	100	59	3.1	100
CURB-65 ≥ 2	8 (8.2)	75	91.8	10.7	99.6
CURB-65 ≥ 3	2 (16.7)	25	99.2	28.6	99
CURB-65 ≥ 4	2 (100)	12.5	100	100	98.9
IDSA/ATS minor criteria					
IDSA/ATS minor criteria ≥ 0	2 (0.3)	100	0	1.3	0
IDSA/ATS minor criteria ≥ 1	4 (1)	87.5	53.7	2.4	99.7
IDSA/ATS minor criteria ≥ 2	4 (3.3)	62.5	86.5	5.7	99.4
IDSA/ATS minor criteria ≥ 3	4 (10.5)	37.5	96	11.1	99.1
IDSA/ATS minor criteria ≥ 4	0 (0)	12.5	98.8	12.5	98.8
IDSA/ATS minor criteria ≥ 5	2 (50)	12.5	99.8	50	98.9

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
analysis (including confounders adjusted for): ROC analysis	**Age, mean (SD):** 47.5 (22.2) **Gender: male, (%):** (49.3) **Nursing home patients, n (%):** NR **Comorbidities, n (%):** NR **Pneumonia severity:** **Tool** / **N patients (%)** **CURB-65** 0: 716 (0)58.2 1: 402 (32.7) 2: 98 (8.0) 3: 12 (1.0) 4: 2 (0.2) **IDSA/ATS minor criteria** 0: 654 (53.2) 1: 402 (1) 2: 4 (3.3) 3: 4 (10.5) 4: 0 (0) 5: 2 (50) **LOS, median (range):** NR				CURB-65 criteria present had a significant increased OR for mortality of 7.547 (95% CI 4.126-13.805, p<0.001] Not clear what the comparison is **Notes:**

Reference	Patient Characteristics	Risk Assessment tools on admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Capelastegui et al. 2006[13] **Study type:** Prospective **Selection / patient setting:** Galdakao teaching hospital, Basque Country, Spain Consecutive cohort of adults admitted to the ED of the Galdakao hospital with a diagnosis of CAP **Addressing missing data/non reliability of data:** Data were missing for>1% of patients for all variables **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** Pneumonia was defined as pulmonary infiltrates on CXR and clinical symptoms consistent with pneumonia (cough, dyspnoea, fever, and/or pleuritic chest pain) **Inclusion criteria:** Adults (≥ 18 years) with a diagnosis of CAP **Exclusion criteria:** HIV-positive, chronically immunosuppressed, hospitalised in the previous 14 days **All patients,** N: 1776 Exclusions reasons: NR **Included** N: 1776 **Age, mean (SD):** 61.8 (20.5) **Age ≥ 65 years, n (%):** 973 (54.8) **Gender: male, n (%):** 1124 (6.33) **Nursing home patients, n (%):** 102 (5.7)	• PSI • CURB-65 • CRB-65	30-day mortality	a) 30-day mortality, n (%): 119 (6.7) b) AUC (95% CI) predicting 30-day mortality: • PSI: 0.888 (0.864-0.912) • CURB-65: 0.870 (0.844-0.895) • CRB-65: 0.864 (0.835-0.892) c) 30-day mortality by severity tool % (deaths/total) **CURB-65** **0** 0 (0/629) **1** 1.1 (4/377) **2** 7.6 (36/474) **3** 21 (47/224) **4** 41.9 (26/62) **5** 60 (6/10) **CRB-65** **0** 0 (0/716) **1** 4.1 (28/686) **2** 18.7 (55/294) **3** 43.5 (30/69) **4** 54.6 (6/11)	**Funding:** NR **Limitations:** CURB-65 was not assessed as a tool for admission criteria **Additional outcomes**: Need for mechanical ventilation was measured [n (%): 18 (1)], but AUC was only reported for 30-day mortality **Notes:**

Reference	Patient Characteristics	Risk Assessment tools on admission (including thresholds used)	Outcomes measures	Results	Comments
	Comorbidities, n (%): Neoplastic disease: 72 (4.1) Liver disease: 62 (3.5) Congestive heart failure: 101 (5.7) Cerebrovascular disease: 144 (8.1) Renal disease: 115 (6.5) **Pneumonia severity, n (%):** PSI I: 520 (29.3) PSI II: 287 (16.2) PSI III: 338 (19) PSI IV: 438 (24.7) PSI V: 193 (10.9) **LOS, mean (SD):** 5.1 (4.3)				

Reference	Patient Characteristics	Risk Assessment tools on admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Chalmers et al. 2008[14] **Study type:** Prospective **Selection / patient setting:** NHS Lothian University Hospitals Division, A&E or medical assessment units. Either self-referral to A&E or GP referral to the medical assessment unit **Addressing missing data/non reliability of data:** NR **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** Pneumonia was defined as pulmonary infiltrates on CXR and ≥ 3 clinical symptoms (cough, sputum production, breathlessness, fever, pleuritic chest pain, haemoptysis, headache, signs of pneumonia on chest auscultation) **Inclusion criteria:** Diagnosis of CAP **Exclusion criteria:** HAP, active malignancy, immunosuppression, pulmonary embolism, patients receiving palliative care **All patients,** N: 1007 **Included** N: 1007 **Age, mean (range):** 66 (50-78) **Gender: male (%):** (49.7) **Nursing home patients:** NR **Comorbidities, (%):** Chronic cardiac failure (20)	• CURB-65 • CRB-65	30-day mortality	30-day mortality: 9.6% AUC (95% CI) predicting 30-day mortality: • CURB-65: 0.76 (0.74-0.79) • CRB-65: 0.74 (0.71-0.77) Prediction of 30 day mortality:	**Funding:** NR **Limitations:** NR **Additional outcomes**: Hypertension, hypotension as prognostic factors for 30-day mortality (OR) **Notes:**

Severity tool	Sensitivity %	Specificity %	PPV %	NPV %
CURB-65	70.1	80.4	20.9	95.7
CRB-65	47.4	87.4	28.6	94.0

Reference	Patient Characteristics	Risk Assessment tools on admission (including thresholds used)	Outcomes measures	Results	Comments
	Cerebrovascular disease (11.6) Diabetes mellitus (10.1) COPD (20.6) **Pneumonia severity, n (%):** NR **LOS:** NR				

Reference	Patient Characteristics	Risk Assessment tools on admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Zuberi et al. 2008[49] **Study type:** Prospective **Selection / patient setting:** Tertiary care Aga Khan University hospital in Karachi, Pakistan. Patients admitted to the emergency department **Addressing missing data/non reliability of data:** **Statistical analysis (including**	**Diagnosis:** CAP was defined as clinical and CXR evidence of acute lung parenchymal infection on admission that was not pre-existing or of any other known cause in a patient not hospitalised for more than 14 days before the onset of symptoms **Inclusion criteria:** Patients (≥ 16 years) admitted to the ED with a diagnosis of CAP **Exclusion criteria:** Pneumonia was not the primary cause of hospital admission, post-obstructive pneumonia, tuberculosis, bronchiectasis, solid organ and haematological malignancies, HIV-infection, immunocompromised patients, nursing home residents **All patients,**	• CURB-65 Low – 0-1 Intermediate – 2 High – 3-5 • CRB-65 Low – 0 Intermediate – 1-2 High – 3-4	30-day mortality	AUC (95% CI) predicting 30-day mortality: • CURB-65: 0.863 • CRB-65: 0.835	**Funding:** NR **Limitations:** • Small number of patients in the high-risk levels of both scores • Recruitment of inpatients who generally have poorer health than outpatients might have introduced bias **Additional outcomes**: **Notes:**

a) Number of patients in each score and 30-day mortality

Risk score	Number of patients, n (%) N = 137	30 day mortality, n (%) N = 18
CURB-65 0	26 (19)	0
CURB-65 1	37 (27)	0
CURB-65 2	38 (27.7)	4 (10.5)
CURB-65 3	29 (21.2)	11 (37.9)
CURB-65 4	6 (4.4)	2 (33.3)
CURB-65 5	1 (0.7)	1 (100)
P value (df = 5) < 0.0001		
CRB-65 0	34 (24.8)	0
CRB-65 1	55 (40.1)	3 (5.5)
CRB-65 2	39 (28.5)	10 (25.6)
CRB-65 3	8 (5.8)	4 (50)
CRB-65 4	1 (0.7)	1 (100)
P value (df = 4) < 0.0001		

b) Correlation of 30 day mortality with severity risk groups

Mortality risk groups		30-day mortality in hospital, n N = 15	30 day mortality after discharge, n N = 3	OR (95% CI)
CURB65	Low (0-1)	0	0	Ref.group
	Intermediate	1	3	

Reference	Patient Characteristics	Risk Assessment tools on admission (including thresholds used)	Outcomes measures	Results					Comments
confounders adjusted for): ROC analysis Fisher's exact test	N: 155 Exclusions reasons: Status (dead or alive 30 days after admission) not available **Included** N: 137 **Age, mean (SD):** 60.4 (18.5) **Age ≥ 65 years, n (%):** 65 (47.7)				(2)				
					High (3-4)	14	0	15.4 (4.6-51.4)	
				CRB65	Low (0-1)	0	0	Ref.group	
					Intermediate (2)	10	3		
					High (3-4)	5	0	11.1 (2.6-46.4)	

Reference	Patient Characteristics	Risk Assessment tools on admission (including thresholds used)	Outcomes measures	Results	Comments
	Gender: male, n (%): 74 (54) **Nursing home patients:** excluded **Comorbidities >10%, n (%):** • Diabetes mellitus: 61 (44.5) • Ischaemic heart disease/chronic heart failure: 48 (35.0) • COPD: 28 (20.4) • Chronic renal failure: 20 (14.6) **Pneumonia severity, n (%): NR** **LOS: NR**			c) Sensitivity, specificity, positive and negative predictive values of the prediction rules	

Severity tool	Sensitivity %	Specificity %	PPV %	NPV %
CURB-65				
≥0	*100*	*0*	*12.7*	*NC*
≥1	*100*	22	16	*NC*
≥2	*100*	53	24	100
≥3	*78*	82	38	96
≥4	*17*	97	42	88
5	*6*	100	100	87
CRB-65				
≥0	*100*	0	13	NC
≥1	*100*	29	17	NC
≥2	*83*	72	31	96
≥3	*28*	97	55	89
4	*6*	100	100	87

NC= non-calculable

Reference	Patient Characteristics	Risk Assessment tools	Outcomes measures	Results	Comments
Author and year: Bauer et al. 2006[7] **Study type:** Prospective, multicentre **Selection / patient setting:** Ten clinical centres across Germany, including hospitals and out-patient departments. Consecutive patients presenting with CAP **Addressing missing data/non reliability of data:** **Statistical analysis (including**	**Diagnosis:** Pneumonia defined as new CXR pulmonary infiltrates and at least one clinical symptom (cough, dyspnoea, fever, purulent sputum, focal chest signs, pleuritic chest pain) **Inclusion criteria:** Patients with a diagnosis of CAP **Exclusion criteria:** Acquisition of pneumonia after hospital admission, severe immunosuppression, pneumonia as an expected terminal event of a severe chronic disabling comorbidity, alternative diagnosis evolving during follow-up **All patients,** N: 2363; 538 outpatients, 1646 hospitalised Exclusion reasons: 179 patients could not be contacted 14 days after inclusion in the study **Included** N: 2184 **Age, mean (SD): Outpatients (OP); Inpatients (IP)** - OP: 53 (17); IP: 66 (18) **Gender: male, n (%):** OP: 250 (47); IP: 986 (60) **Nursing home patients, n (%):** NR **Comorbidities > 5%, n (%):** Neoplastic disease: OP: 39 (7); IP: 189 (12) Chronic heart failure: OP: 36 (7); IP: 447 (28) Diabetes mellitus: OP: 45 (8); IP: 347 (21) Renal disease: OP: 11 (2); IP: 172 (11) Cerebrovascular disease: OP: 22 (4); IP: 275 (17) Pulmonary disease: OP: 163 (31); IP: 600 (37) **Pneumonia severity, n (%):** **Risk categories** | **CURB** | **CRB** | **CRB-65**	• CURB • CRB • CRB-65	30-day mortality	a) 30-day mortality: 4.3% b) AUC (95% CI) predicting 30-day mortality: • CURB: 0.793 (0.745-0.841) • CRB: 0.721 (0.654-0.787) • CRB-65: 0.785 (0.736-0.833) c) Mortality at 30 days according to CURB, CRB and CRB-65 for patients with all data sets complete: **Outpatients, N = 208** | **Inpatients, N = 1135** **CURB** 0: 0/141 | 2/399 1: 0/56 | 23/450 2: 1/9 | 28/234 3: 1/2 | 11/45 4: nr | 2/7 **CRB** **0**: 0/165 | 17/645 **1**: 1/37 | 30/402 **2**: 1/5 | 16/78 **3**: nr | 3/10 **CRB65** **0**: 0/115 | 0/268 **1**: 0/80 | 21/524 **2**: 1/10 | 31/283 **3**: 1/3 | 12/53 **4**: nr | 2/7	**Funding:** German Ministry of Education and Research. Dr Bauer was supported by official grants of the Ruhr-University Bochum **Limitations:** • Potential selection bias could have influenced the observed Mortality and the ratio of in- and outpatients might not be representative • Missing data, however authors are confident on the validity of the results

confounders adjusted for): ROC analysis	0	540	10	63							**Additional outcomes**: **Notes:**
	1	506	83	293							
	2	243	440	604							
	3 or 4	54	810	383							
	LOS, mean (SD): NR										

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Varshochi 2013[46] **Study type:** Prospective study during a period of 21 months **Selection / patient setting:** Two educational hospital centers in Iran(Imam Reza and Sina in Tabriz) **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):**	**Inclusion criteria:** Patients with CAP; acute respiratory symptoms (cough, sputum, fever and dyspnoea), physical exam findings (percussion dullness, crackle, evidence of consolidation) and radiologic findings in favour of pneumonia. **Exclusion criteria:** Pulmonary embolism, pulmonary cancer, decompounded congestive heart failure, pulmonary oedema, and if they were diagnosed before or during hospital stay. **All patients,** N: 134 Exclusions reasons: NR **Included** N: 134 **Age, mean (SD):** 64.2 (19.8%) **Age ≥ 65 years, n (%):** 58 (43.3%) **Gender: male, n (%): 87** (64.9%) **Nursing home patients, n (%):** 2 (1.5%) **Comorbidities, n (%):** Altered mental status: 35 (26.1) Liver disease: 1 (0.7) Congestive heart failure: 48 (35.8) Cerebrovascular disease: 25 (18.7)	• PSI (I to V) • CURB-65 (0 to 5) (collected upon admission)	In hospital mortality: 35 (26.1%) **Results** Mortality rates based on PSI and CURB-65 classifications	**Funding:** Supported by Research Center of Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences, Tabriz, Iran **Limitations:** No definition of CAP was given **Notes:**

PSI score	Mortality	P value	AUC (95% CI)
I and II (n = 22)	0 (0)	<0.001	0.77 (0.69-0.85)
III (n = 21)	2 (9.5)		
IV (n = 40)	8 (20)		
V (n = 51)	25 (49)		

CURB 65 score	Mortality	P value	AUC (95% CI)
0 and 1 (n = 22)	3 (13.6)	< 0.001	0.74 (0.65-0.84)
2 (n = 52)	3 (5.8)		
3 (n = 43)	21 (48.8)		
4 & 5 (n = 17)	8 (47.1)		

Data are shown as frequencies (%)

	Sensitivity	Specificity
PSI ≥ IV	80	66.7
CURB-65 ≥ 2	82.9	68.7

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
	Renal disease: 43 (32.1) Malignancy: 16 (11.9) Pleural effusion: 24 (17.9) Using mechanical ventilation: 39 (29.1) **Pneumonia severity, n (%):** PSI I: 4 (3) PSI II: 18 (13.4) PSI III: 21 (15.7) PSI IV: 40 (29.9) PSI V: 51 (38.1) **Hospitalization duration (days):** 9.33 (5.24)			

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Luque 2012[32] **Study type:** Prospective study **Selection / patient setting:** all consecutive patients hospitalized with CAP during 2009 in a tertiary hospital in Barcelona **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):**	**Inclusion criteria:** Patients with CAP; presence of respiratory signs and symptoms (dry or conducive cough, pleural pain or dyspnoea), fever, auscultatory findings of abnormal breath sounds and crackles, together with the identification of an infiltrate on the chest X ray . **Exclusion criteria:** Paediatric patients, immunosuppressed subjects (those with HIV or patients receiving chemotherapy) and patients directly admitted to ICU, patients with clinical confirmation of an alternative diagnosis other than pneumonia, or the administration of an antibiotic treatment different from the protocol in the centre (a third generation cephalosporin associated to macrolide drug). **All patients,** N: 152 Exclusions reasons: NR **Included** N: 134 **Age, mean (SD):** 73 (70.6-75.4)	• PSI (I to V) • CURB-65 (0 to 5) (collected upon admission)	30 day mortality: 18 (11.8%) In hospital mortality: 20 (13.2%) **Results** 30-day mortality rates based on PSI and CURB-65 classifications	**Funding:** Supported by Research Center of Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences, Tabriz, Iran **Limitations:** **Notes:** the study also compared the ability of Mortality Probability Model II (MPM-II) to predict mortality in CAP patients

PSI score	Mortality	P value	AUC (95% CI)
I and II (n = 10)	0 (0)	0.017	0.71 (0.59-0.84)
III (n = 28)	1 (3.6)		
IV (n = 62)	6 (9.7)		
V (n = 52)	11 (21.2)		

CURB 65 score	Mortality	P value	AUC (95% CI)
0 and 1 (n = 47)	2 (4.2)	< 0.001	0.74 (0.62-0.87)
2 (n = 46)	3 (6.5)		
3 (n = 35)	5 (14.3)		
4 & 5 (n = 24)	8 (33.3)		

Data are shown as frequencies (%)

	Sensitivity	Specificity
PSI ≥ IV (Fine et al defining low CAP (I-III) and	0.944	0.269

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures			Comments
	Gender: male, n (%): 105 (69.1%) **Nursing home patients, n (%):**15 (10.3%) **Comorbidities, n (%):** Cardiovascular: 73 (48) COPD or asthma: 62 (40.8) Diabetes mellitus: 32 (21.1) Renal disease: 36 (23.7) Neurological disease: 32 (21.1) Hepatobiliary disease: 15 (9.9) **Pneumonia severity, n (%):** PSI I: 7 (4.6) PSI II: 3 (2) PSI III: 28 (18.4) PSI IV: 62 (40.8) PSI V: 52 (34.1) **Length of hospital stay (days):** 13 (11.6-14.4)		high risk (IV-V)			
			CURB-65 ≥ 2 (Lim et al defining low CAP (0 and 1) or high risk (2-5)	0.889	0.336	

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Aujesky 2005A[5] **Study type:** Prospective study **Selection / patient setting:** all eligible patients hospitalized with CAP from 32 hospital emergency departments (ED) (January- December 2001) in Pennsylvania and Connecticut. **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):**	**Inclusion criteria:** Patients > 18 years old with a clinical diagnosis of pneumonia and a new radiographic infiltrate. **Exclusion criteria:** Patients with hospital-acquired pneumonia, immunosuppression or comorbid conditions that distinguished them diagnostically or therapeutically from pneumonia, or psychosocial problems incompatible with outpatient treatment, enrolment or follow up, pregnant, previously enrolled or enrolled in a competing research. **All patients,** N: 3181 Exclusions reasons: NR **Included** N: 3181 **Age≥65 years, n (%):** 1747 (55%) **Gender: male, n (%): 1540** (48.4%) **Nursing home patients, n (%):** 130 (4%) **Comorbidities, n (%):** Congestive heart failure: 431 (14) Cerebrovascular disease: 268 (8) Malignancy: 87 (3)	• PSI (I to V) • CURB • CURB-65 (0 to 5) (collected upon admission or the first available measurement after the time of presentation to ED)	30 day mortality: 145 (4.6%) **Results** 30-day mortality rates based on PSI and CURB-65 classifications	**Funding:** By a grant RO1 HS10049-03 from the Agency for Healthcare Research and Quality, Rockville, Maryland. **Limitations:** for the 2 CURB scores, the item of presence of confusion was not defined by using an Abbreviated Mental Test Score<=8 or new disorientation to person, place or time. Instead the item of altered mental status was used as a

PSI score	Mortality	Likelihood ratio (95% CI)	AUC (95% CI)
I (n = 686)	2 (0.3)	0.06 (0.03-0.2)	
II (n = 774)	3 (0.4)	0.08 (0.03-0.3)	0.81 (0.78-0.84)
III (n = 692)	26 (3.8)	0.82 (0.6-1.2)	
IV (n = 829)	67 (8.1)	1.8 (1.5-2.2)	
V (n = 200)	47 (24)	6.4 (4.9-8.5)	

CURB 65 score	Mortality	Likelihood ratio (95% CI)	AUC (95% CI)
0 (n = 1051)	6 (0.6)	0.12 (0.05-0.3)	
1 (n = 901)	27 (3.0)	0.65 (0.5-0.9)	0.76 (0.73-0.80)
2 (n = 775)	47 (6.1)	1.4 (1.1-1.7)	

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
	Renal disease: 108 (3) Liver disease: 29 (1) **Pneumonia severity, n (%):** PSI I: 686 (22) PSI II: 774 (24) PSI III: 692 (22) PSI IV: 829 (26) PSI V: 200 (6)		3 (n = 383) | 51 (13) | 3.2 (2.5-4.1) 4 (n = 64) | 11 (17) | 4.4 (2.3-8.1) 5 (n = 7) | 3 (43) | 16 (3.6-70) **CURB score** | Mortality | Likelihood ratio (95% CI) | AUC (95% CI) 0 (n = 1635) | 28 (1.7) | 0.35 (0.3-0.5) | 0.73 (0.68-0.76) 1 (n = 1035) | 49 (4.7) | 1 (0.8-1.3) 2 (n = 431) | 53 (12) | 2.9 (2.3-3.7) 3 (n = 73) | 12 (16) | 4.1 (2.3-7.5) 4 (n = 7) | 3 (43) | 16 (3.6-70) Data are shown as frequencies (%) | | Sensitivity | Specificity | PPV | NPV | PSI ≥ IV * | 79% (71-85) | 70% (68-72) | 11% (9-13) | 99% (98-99) | CURB-65 ≥ 2^ | 77% (70-84) | 63% (62-65) | 9% (7-11) | 98% (98-99) | CURB ≥ 1^ | 81% (73-87) | 53% (51-55) | 8% (6-9) | 98% (98-99) | *Fine et al defining low CAP (I-III) and high risk (IV-V) ^ Lim et al defining low CAP (0 and 1) or high risk (2-5)	proxy measure for confusion. **Notes:** the study also did a secondary comparison by testing whether a 2-step approach as used in the PSI would improve the predictive performance of the CURB.

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Ananda-Rajah 2008[3] **Study type:** Retrospective study **Selection / patient setting:** all eligible patients hospitalized with CAP from a university affiliated hospital for 12 months in Australia (part of the multi-centre PORT study). **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** univariate analysis, frequencies, sensitivity, specificity, positive and negative predictive value	**Inclusion criteria:** Patients > 18 years old, admission for at least 24 h, principal discharge diagnosis of pneumonia according to ICD-10 AM (Australian), CXR performed within 24 h of admission and haematology and serum biochemistry assessment within 24 h of admission. Medical records were reviewed to confirm the diagnosis of CAP, which was defined as 1 or more symptoms suggestive of CAP (cough, sputum production and fever) plus chest radiograph evidence confirmed by a radiologist. **Exclusion criteria:** Patients with HIV infection, tuberculosis, aspiration pneumonitis or admission to any hospital within the preceding 14 days. **All patients,** N: 1299 Exclusions reasons: normal chest X-ray or because of admission to a hospital within the preceding 14 days. **Included** N: 390 **Age, mean (SD):** 72 (16) **Gender: male, n (%):** 229 (56.1%)	• PSI (I to V) • CURB-65 (0 to 5) (collected upon admission or the first available measurement after the time of presentation to ED)	- 30 day mortality: 63 (15.4%) - ITU admission: 43 (10.5%) **Results** 30-day mortality rates based on PSI and CURB-65 classifications **PSI score (number of episodes)** / Mortality (number of patients) / ICU admission (number of patients): I/II (n = 49): 1 (2) / 1 (2) III (n = 65): 3 (4.6) / 5 (7.7) IV (n = 181): 23 (12.7) / 23 (12.7) V (n = 113): 36 (31.9) / 14 (12.4) **CURB 65 score** / Mortality / ITU admission (number of patients): 0 (n = 26): 0 / 0 1 (n = 94): 8 (8.5) / 7 (7.4) 2 (n = 133): 16 (12) / 10 (7.5) 3 (n = 107): 20 (18.7) / 20 (18.7) 4 & 5 (n = 48): 19 (36.6) / 6 (12.5) Data are shown as frequencies (%) Sensitivity % (95% CI) / Specificity % (95% CI) / PPV % (95% CI) / NPV % (95% CI): PSI ≥ IV (Fine et al: 93.7 (84.5- / 31.9 (27-37.1) / 20.1 (15.6- / 96.5 (91.2-	**Funding:** NA **Limitations:** the retrospective design of the study may have resulted in under reporting of such variables such as confusion thus lowering the overall scores of PSI, CURB-65 **Notes:** the study also did a secondary comparison by excluding patients who didn't have a resuscitation order within

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures					Comments
	Nursing home patients, n (%): 38 (9.3%) **Comorbidities, n (%):** Liver disease: 11 (2.7) Congestive heart failure: 105 (25.7) Cerebrovascular disease: 56 (13.7) Renal disease: 72 (17.6) Malignancy: 61 (15) Not for resuscitation order within 24h: 73 (17.9) **Pneumonia severity, n (%):** PSI I/II: 49 (12.6) PSI III: 65 (16.6) PSI IV: 181 (46.4) PSI V: 113 (28.9) **Hospitalization duration, mean days (range):** 10.7 (2-91)		defining low CAP (I-III) and high risk (IV-V)	98.2)		25.1)	99.0)	24 h of admission.
			CURB-65 ≥ 3 (Lim et al defining low CAP (0 and 1) or high risk (2-5)	61.9 (48.8-73.9)	66.4 (61.1-71.3)	25.2 (25.1-43)	90.5 (86.2-93.8)	
			CURB-65 ≥ 2	87.3 (76.5-94.4)	32.5 (27.5-37.7)	19.1 (14.7-24.1)	93.3 (87.3-97.1)	
			AUC for PSI and CURB-65 was 0.72 and 0.69 respectively.					

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Tejera 2007[44] **Study type:** Prospective study **Selection / patient setting:** patients who were admitted for pneumonia and presented at the emergency room of the hospital Universitario de Canarias (Spain) were included. **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** frequencies, AUC, results from a multivariate analysis (RR, 95% confidence interval)	**Inclusion criteria:** Patients were included after evaluation in the emergency room. CAP was defined as an acute illness associated with 1 or more of the following: new cough with or without sputum production, pleuritic chest pain, dyspnoea, fever or hypothermia, altered breath sounds on auscultation, leucocytosis, plus the presence of a new infiltrate on a chest radiograph evidence in patients who had not been hospitalized within the previous month and in whom no alternative diagnosis has emerged during follow up. **Exclusion criteria:** Patients with HIV infection, tuberculosis, aspiration pneumonitis or admission to any hospital within the preceding 14 days. **All patients,** N: 226 Exclusions reasons: na **Included** N: 226 **Age > 85 yrs:** 39 (17.2%) **Gender: male, n (%):** 145 (64.2%) **Comorbidities, n (%):**	• PSI (I to V) • CURB-65 (0 to 5) (collected upon admission to ED)	Mortality (as an end point during admittance): 28 (12.4%) **Results** **PSI score (number of patients)** / Mortality (number of patients) / AUC I (n = 22) / 0 / 0.752 (0.669-0.836) II (n = 3) / 0 III (n = 31) / 1 IV (n = 82) / 11% V (n = 88) / 20.5% **CURB-65 score (number of patients)** / Mortality (number of patients) / AUC 0 (n = 17) / 0 / 0.784 (0.669-0.869) 1 (n = 33) / 3% 2I (n = 72) / 4.2% 3 (n = 58) / 13.8% 4 (n = 39) / 35.9% 5 (n = 7) / 28.6% Results from a multivariate analysis (including age (85 years or more), dehydration, subjective nutritional score, hand grip (dynamometry), Glasgow coma score, severity of sepsis, PSI, CURB-65, TNFa, IL-6, Strem-1 and IGF-1. Among the variables with predictive independent value	**Funding:** NA **Limitations:** the outcome of mortality as collected was not time specific **Notes:** the aim of the paper was to test the prognostic ability of triggering receptor expressed on myeloid cells-1 (TREM-1) on CAP

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
	Dementia: 41 (18.1%) Renal disease: 44 (19.4%) Severe sepsis: 98 (43.3%) **Pneumonia severity, n (%):** PSI I: 22 (9.7%) PSI II: 3 (1.3%) PSI III: 31 (13.7%) PSI IV: 82(36.3%) PSI V: 88 (38.9%)		were IGF-1 less than 37.5 ng/ml (RR 10.2 (3.2-32.5), CURB-65 > 3 (RR 3.3 (1.2-9), TREM-1 > 50 pg/ml (RR 7 (2.3-21), age > 85 years old (RR 6.2 (2.1-18.3), and IL-6 > 80pg/ml (RR 2.9 (1.01-8.2). With these five data, the AUC increases to 0.917 (0.857-0.977).	

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Ochoagondar 2011[35] **Study type:** Population based prospective study	**Inclusion criteria:** Pneumonia was defined when a new infiltrate on a chest radiograph was identified with one major criteria (cough, expectoration or fever) or two	• PSI (I to V) • CURB-65 (0 to 5) •CRB-65 (0 to 4) (collected upon admission to ED)	30 days mortality: 80 (13.6%)	**Funding:** Grant from the instituto de Salud Carlos III from the Spanish

Selection / patient setting: community dwelling patients 65 years old and older who had radiographically confirmed CAP (hospitalised or outpatients) from three reference hospitals in the region of Tarragona (Spain) between 2002 and2008. The main sources of data were the hospital discharge databases of the hospitals together with the hospital and primary care clinical records of case patients. These clinical records were used to identify and validate hospitalised and outpatient CAP cases.

Addressing missing data/non reliability of data:

Statistical analysis (including confounders adjusted for): frequencies, AUC, results from a multivariate analysis (RR, 95% confidence interval)

minor criteria (dyspnoea, pleuritic pain, altered mental status, pulmonary consolidation on auscultation and leucocytosis).

Exclusion criteria:
Nosocomial pneumonia, readmissions or other diagnoses.

All patients,
N: 649
Exclusions reasons: 59 did not have available analytical data for PSI and CURB-65.

Included N: 590

Age (mean): 77.4 (SD7.6)
Gender: male, n (%): 63.2%

Comorbidities, n(%):
Chronic pulmonary disease: 225 (38.1%)
Diabetes mellitus: 160 (27.1%)
Chronic heart disease: 152 (25.8%)
Chronic liver disease: 26 (4.4%)
Cerebrovascular disease: 38 (6.4%)
Renal disease: 45 (7.6%)
Cancer: 35 (5.9%)
Smoking: 75 (12.7%)
Corticosteroid therapy: 78 (13.2%)

Pneumonia severity, n (%):
PSI II: 61 (10.3%)
PSI III: 160 (27.1%)
PSI IV: 264 (44.7%)
PSI V: 105 (17.8%)

Results

PSI score (number of patients)	30-day mortality	AUC
I (n = 0)	0	0.73 (0.67-0.79)
II (n = 61)	0	
III (n = 160)	11 (6.9)	
IV (n = 264)	38 (14.4)	
V (n = 105)	31 (29.5)	

CURB 65 score	Mortality	AUC
0 (n = 0)	0	0.67 (0.61-0.74)
1 (n = 293)	22 (7.5)	
2 (n = 220)	32 (14.5)	
3 (n = 60)	16 (26.7)	
4 (n = 15)	8 (53.3)	
5 (n = 2)	2 100)	

CRB 65 score	Mortality	AUC
0 (n = 0)	0	0.72 (0.66-0.78)
1 (n = 411)	27 (6.6)	
2 (n = 138)	36 (26.1)	
3 (n = 37)	15 (40.5)	
4 (n = 4)	2 (50)	

	Sensitivity % (95% CI)	Specificity % (95% CI)	PPV % (95% CI)	NPV % (95% CI)
PSI				
≥ III	100 (94.3-100)	12 (9.34-15.2)	15.1(12.2-18.5)	100(92.6-100)
≥ IV	86.3(76.3-92.6)	41.2(36.9-45.6)	18.7(14.9-23.1)	95(91-97.4)
V	38.7(28.3-50.3)	85.5(82.1-88.4)	29.5(21.2-39.3)	89.9(86.8-92.4)
CURB-65				
≥ 2	72.5(61.2-81.6)	53.1(48.7-57.5)	19.5(15.3-24.6)	92.5(88.7-95.1)

Science and Innovation Ministry

Limitations:

Notes: the authors did also a subgroup analysis for those aged 65-74 and ≥ 75 years old and they found that the discriminatory power (AUC) of the three rules was slightly better in younger (65-74) than older(≥ 75) patients.

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Alavi-Moghaddam 2013[2] **Study type:** prospective study **Selection / patient setting:** patients 65 years old and older who had clinically and radiographically confirmed CAP referred to the emergency department of Imam Hossein Medical Centre (Iran) in 2009. **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** frequencies, sensitivities, specificities, positive and negative predictive values, AUC	**Inclusion criteria:** Pneumonia was defined on the grounds of their clinical and paraclinical findings by the emergency and/or infectious disease residents and/ or specialists. **Exclusion criteria:** Patients whose diagnosis changed during the course of treatment. **All patients,** N: 200 Exclusions reasons: not given **Included** N: 200 **Age in years (mean):** 68 (SD 18) **Gender: male, n (%):** 122 (60%) **Underlying conditions;** the most common underlying condition in the whole population was heart failure. The most common cause of the condition in males under the age of 50 was drug injection abuse and high blood glucose whereas in females of the same age, viral diseases (influenza) and high blood glucose were the prevailing causes.	• PSI (I to V) • CURB-65 (0 to 5) (collected upon admission to ED)	30 days mortality: 36 (18%) ICU admission: 30 (15%) **Results** **PSI score (number of patients)** / 30-day mortality: I (n=4): 0 II (n = 3): 0 III (n = 13): 0 IV (n = 103): 0 V (n = 77): 36 (46.7%) **CURB 65 score** / 30-day Mortality: I (n = 4): 0 II (n = 3): 0 III (n = 13): 0 IV (n = 103): 0 V (n = 77): 36 (46.7%) **In predicting mortality** PSI II: Sensitivity % (95% CI) 100 (90.4-100); Specificity % (95% CI) 2.4 (0.9-6.1); PPV % (95% CI) 18.4(13.6-24.4); NPV % (95% CI) 100(51-100)	**Funding: NA** **Limitations:** The authors mentioned that the number of patients admitted to ICU may have been underestimated as it is possible that certain patients were admitted to other wards due to unavailability of ICU beds (influenced by physician's decision). **Notes:** the authors also reported the results of an analysis of underlying conditions and mortality; they found that heart failure, age, low blood

III	100 (90.4-100)	4.3(2.1-8.5)	18.7(13.8-24.7)	100(64.6-100)	pH and high urea levels, and decreased consciousness level were statistically significant with mortality (p<0.05)
IV	100 (90.4-100)	12.2(8.8-18.1)	20(14.8-26.4)	100(83.4-100)	
V	100 (90.4-100)	75 (67.9-81)	46.8(36-57.8)	100 (98-100)	
CURB-65					
I	100 (90.4-100)	0.6 (0.1-3.4)	18.1(13.4-24)	100(20.6-100)	
II	100 (90.4-100)	5.5 (2.9-10.1)	18.9(13.9-25)	100(70.1-100)	
III	100 (90.4-100)	82.3 (75.8-87.4)	55.4(43.4-66.8)	100(97.2-100)	
IV	75 (58.9-86.3)	97 (93.1-98.7)	84.4(68.3-93.4)	94.6(90.1-100)	
V	11.1(4.4-25.3)	99.4 (96.6-99.9)	80(37.6-96.4)	83.6(77.8-88.1)	

In predicting ICU admission

	Sensitivity % (95% CI)	Specificity % (95% CI)	PPV % (95% CI)	NPV % (95% CI)
PSI				
II	100 (92.9-100)	2.7 (1.0-6.7)	25.5(19.9-32)	100(51-100)
III	100 (92.9-100)	4.7(2.3-9.3)	25.9(20.2-32.5)	100(64.6-100)
IV	100 (92.9-100)	13.3(8.8-19.7)	27.8(21.8-34.7)	100(83.9-100)
V	90 (78.6-95.7)	78.7 (71.4-84.5)	58.4(47.3-68.8)	95.9(90.8-98.3)
CURB-				

65				
I	100 (88.7-100)	0.7 (0.1-3.7)	16.8(12-22.9)	100(20.7-100)
II	100 (88.7-100)	6 (3.2-11)	17.5(12.6-23.9)	100(70.1-100)
III	96.7 (83.3-99.4)	89.3 (83.4-93.3)	64.4(49.8-76.8)	99.3(95.3-99.9)
IV	30 (16.7-47.9)	98 (94.3-99.3)	75(46.8-91.1)	87.5(81.7-91.7)
V	16.7(7.3-33.6)	100 (97.5-99.9)	100(56.6-100)	85.7(79.8-80.1)

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Lee 2013[30] **Study type:** Retrospective study **Selection / patient setting:** retrospective analysis of a prospective registry database of all consecutive patients with CAP who visited the emergency department and hospitalised in a tertiary academic hospital (950-bed). **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** frequencies, AUC, results from a multivariate analysis (RR, 95% confidence interval)	**Inclusion criteria:** Hospitalised patients older than 18 years old with CAP which was defined as evidence of a pulmonary infiltrate on chest radiograph and symptoms consistent with pneumonia, including cough, dyspnoea, fever and/ or pleuritic chest pain which were not acquired in a hospital or nursing home. If a pulmonary infiltrate was absent on the initial chest radiograph, abnormal lung sounds on the initial physical examination and pulmonary infiltrate on a follow-up chest radiograph were accepted as equivalent. **Exclusion criteria:** Patients younger than 18 years, had been transferred from another hospital, was discharged form a hospital within the past 10 days, experienced an episode of pneumonia within the past 30 days, exhibits active pulmonary tuberculosis, has known HIV positivity, or is chronically immunosuppressed. **All patients,** N: 744	• PSI (I to V) • CURB-65 (0 to 5) (collected upon admission to ED)	30 days mortality: 100 (13.4%) **Results** **PSI score (number of patients)** / **30-day mortality** / **AUC (95% CI)** I/II (n = 132) / 2 (1.5%) / 0.74 (0.70-0.79) III (n = 136) / 4 (2.9%) IV (n = 300) / 41 (13.7%) V (n = 176) / 53 (30.1%) **CURB 65 score** / **30-day Mortality** / **AUC (95% CI)** 0 (n = 96) / 2 (2.1%) / 0.74 (0.69-0.79) 1 (n = 214) / 11 (5.1%) 2 (n = 253) / 36 (14.2%) 3 (n = 133) / 27 (20.3%) 4 (n = 38) / 16 (42.1%) 5 (n = 10) / 28 (80%) **Results of multivariate logistic analysis* in predicting 30-day mortality** **PSI** / **Odds ratio (95% CI)** / **P value** I/ II / Reference III / 1.47 (0.24-8.93) / 0.648	**Funding:** partially supported by grant number 02-2010-025 from SNUBH research fund. **Limitations:** the aim of the paper to evaluate the association of red cell distribution width with mortality in patients with CAP. **Notes:** the authors also reported the results ICU admission and vasopressor use by quartile of red cell distribution

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures			Comments
	Exclusions reasons: medical records were not available for 10 patients and patients were identified as having been transferred to other facilities. **Included** N: 721 **Age in years (mean):** 70.1 (SD 15) **Gender: male, n (%):** 32% **Comorbidities, n (%);** Hearth failure: 18 (2.4%) Renal failure: 83 (11.2%) Liver disease 44 (5.9%) COPD: 158 (9.9%) Neoplasm: 195 (26.2%) Neurologic condition: 187 (25.1%) Diabetes mellitus: 222 (29.8%) **PSI class:** I, II: 132 (17.7%) III: 136 (18.3%) IV: 300 (40.3%) V: 176 (23.7%) **CURB-65:** 0: 96 (12.9%) 1: 214 (28.8%) 2: 253 (34%) 3: 133 (17.9%) 4: 38 (5.1%) 5: 10 (1.3%)		IV V CURB-65 0 1 2 3 4 5	4.76 (1.01-22.53) 7.10 (1.42-35.42) Reference 1.34 (0.25-7.20) 2.26 (0.45-11.30) 2.44 (0.46-12.82) 3.42 (0.58-20.06) 37.02 (2.49-550.32) * other variables in the analysis: quartile of red cell distribution width, haematocrit, mean corpuscular haemoglobin, albumin, cholesterol, prothrombin time	0.049 0.017 0.730 0.323 0.292 0.174 0.009	width but not by assessment tool.

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Man 2007[33] **Study type:** Prospective study **Selection / patient setting:** consecutive patients admitted to hospital (the main teaching hospital of the Faculty of Medicine of the Chinese University of Hong Kong) through the emergency department with a provisional diagnosis of CAP between 1st January and 31st December 2004. **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** frequencies, AUC, results from a multivariate analysis (RR, 95% confidence interval)	**Inclusion criteria:** All patients older than 17 years old admitted to hospital with CAP which was defined as acute infection of the pulmonary parenchyma accompanied by the presence of an acute pulmonary infiltrate on chest radiograph in a patient not hospitalised for more than 14 days before onset of symptoms. The final diagnosis was made by a respiratory physician and was based on the clinical, radiological and laboratory results. **Exclusion criteria:** Patients with severe immunosuppression (HIV infection, neutropenia < 1x 10^9/l , on long term immunosuppressants or steroids, or solid organ transplant recipients), patients with a final diagnosis of tuberculosis, patients who had been in hospital within the previous 14 days and those with a diagnosis other than CAP after admission. **All patients,** N: 1648 Exclusions reasons: 632 (38%) were excluded did not meet inclusion criteria.	• PSI (I to V) • CURB-65 (0 to 5) • CRB-65 (0-4) (collected upon admission to ED)	30 days mortality: 87 (8.6%) ICU admission: 41 (4.0%) **Results** **PSI score (number of patients)** / **30-day mortality** (AUC: 0.736 (0.687-0.786)) / **ICU admission** Low (II/III)(n = 480): 14 (2.9%) / 13 (2.7%) Intermediate (IV) (n = 355): 33 (9.3%) / 16 (4.5%) High (V) (n = 181): 40 (22.1%) / 12 (6.6%) **CURB 65 score** / **30-day Mortality** (AUC: 0.733 (0.689-0.787)) / **ICU admission** Low (0-1) (n = 440): 13 (3%) / 10 (2.3%) Intermediate (2) (n = 315): 23 (7%) / 14 (4.4%) High (3-5) (n = 261): 51 (19.5%) / 17 (6.5%) **CRB 65 score** / **30-day Mortality** (AUC: 0.694 (0.634-0.753)) / **ICU admission** Low (0) (n = 128): 3 (2.3%) / 5 (3.9%) Intermediate (1- : 58 (7.4%) / 26 (3.3%)	**Funding:** na **Limitations:** the definition of confusion in the CURB-65 was not based on Abbreviated Mental Test Score of ≤ 8 but on Glasgow Coma Scale of ≤ 14 (as too many dialects are used in Hong Kong) **Notes:** the authors also reported that there was a statistically significant trend of increasing mortality with worsening

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
	Included N:1016 **Age in years (mean):** 72 (SD 17) **Gender: male, n (%):** 583 (57.4%) **Nursing home residents**: 243 (24.3%) **Comorbidities (> 5%), n (%);** Congestive health failure: 124 (12.2%) Renal failure: 84 (8.3%) COPD: 167 (16.4%) Cerebrovascular disease: 176 (17.3%) Old pulmonary tuberculosis: 85 (8.4%) **PSI class:** I: 0 II: 242 (23.8%) III: 238 (23.4%) IV: 355 (34.9%) V: 181 (17.8%) **CURB-65:** 0: 107 (10.5%) 1: 333 (32.8%) 2: 315 (31%) 3: 189 (18.6%) 4: 64 (6.3%) 5: 8 (0.8%) **CRB-65:** 0: 128 (12.6%) 1: 489 (48.1%) 2: 294 (28.9%) 3: 95 (9.4%) 4: 10 (1%)		2) (n = 783) High (3-4) (n = 105) — 26 (24.8%) — 10 (9.5%) **In predicting 30-day mortality** **PSI** ≥ II — 100 — 0 — 8.6 — Na ≥ III — 97.7 — 25.8 — 11 — 99.2 ≥ IV* — 83.9 — 50.2 — 13.6 — 97.1 ≥ V — 46 — 84.8 — 22.1 — 94.4 **CURB-65** ≥ 0 — 100 — 0 — 8.6 — Na ≥ 1≥ 2* — 98.9 — 11.4 — 9.5 — 99.1 ≥ 3 — 85.1 — 46 — 12.8 — 97 ≥ 4 — 58.6 — 77.4 — 19.5 — 95.2 ≥ 5 — 23 — 94.4 — 27.8 — 92.9 3.4 — 99.5 — 37.5 — 91.7 **CRB-65** ≥ 0 — 100 — 0 — 8.6 — Na ≥ 1* — 96.6 — 13.5 — 9.5 — 97.7 ≥ 2 — 67.8 — 63.4 — 14.8 — 95.5 ≥ 3 — 29.9 — 91.5 — 24.8 — 93.3 ≥ 4 — 4.6 — 99.4 — 40 — 91.7 *thresholds to define low risk groups	risk groups in all risk severity tools (p<0.001). ICU admission rates also increased with the risk levels of each rule but were only statistically significant in CURB-65 and CRB-65.

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Abisheganaden 2012[1] **Study type:** Retrospective study using secondary analyses of medical records and administrative data. **Selection / patient setting:** first hospital episodes of adults aged 55 years or older with the principal diagnosis of CAP in the 12 months of 2007 in three acute-care public hospitals in Singapore. **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** frequencies, AUC, results from a univariate analysis (ORs, 95% confidence interval)	**Inclusion criteria:** CAP diagnosed by presence of acute symptoms or signs of pneumonia accompanied by the presence of an acute pulmonary infiltrate on CXR less than 24 h before and less than 48 h after hospital admission. **Exclusion criteria:** Patients who were residents in long term facilities, undergoing chemotherapy, haemodialysis and intravenous antibiotics or wound care in the prior 30 days, HIV infection, neutropenia < 1x 10^9/l , on long term and patients who had been in hospital within the previous 14 days and those with unavailable medical records. **All patients,** N: 3180 Exclusions reasons: 2019 were excluded as they did not meet inclusion criteria, 19 had second and subsequent hospital episodes **Included** N:1052 **Age in years (mean):** 76.7 (SD 10.6) **Gender: male, n (%):** 489 (56.1%) **Comorbidities (> 5%), n (%);** Stroke: 220 (20.9%)	• PSI (I to V) • CURB-65 (0 to 5) • Enhanced CURB (plus age, metastatic cancer, solid tumour without metastasis, stroke) (collected upon admission to ED)	30 days mortality: 181 (17.2%) **Results** **PSI score** / **30-day mortality** III (n = 162) / 3 (1.9%) III (n = 342) / 20 (5.9%) IV (n = 394) / 87 (22.1%) V (n = 154) / 71 (46.1%) **CURB 65 score** / **30-day Mortality** O (n = 115) / 5 (4.4%) 1 (n = 439) / 40 (9.1%) 2 (n = 390) / 90 (23.1%) 3 (n = 98) / 39 (39.8%) 4/5 (n = 10) / 7 (70%) **Score: Predictive variable** / **OR (95% CI)** / **AUC (95% CI)** **PSI (II as a reference)** / 0.77 (0.73 to 0.79) ***III*** / 3.29 (0.96 to 11.24) ***IV*** / 15.02(4.68 to 48.24) ***V*** / 45.34 (13.86 to 148.33) **CURB-65 (0 as a reference)** / 0.70 (0.66 to 0.74) ***1*** / 2.21 (0.85 to 5.72) ***2*** / 6.60 (2.61 to 16.67) ***3*** / 14.54 (5.44 to 38.87) ***4 & 5*** / 51.33 (10.13 to 260.04) **Enhanced CURB (0 as a reference)** / 0.80 (0.77 to 0.83)	**Funding:** National Medical Research Council. **Limitations:** The study did not account for do-not-resuscitate (DNR) status due to inconsistent DNR documentation in routine charts at the hospitals (which is probably an additional risk factor for short term mortality) **Notes:** the authors developed an enhanced CURB score using a statistical

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures			Comments
	Dementia: 125 (11.9%) Solid tumour without metastasis: 111 (10.6%) Renal failure: 113 (10.7%) Depression: 62 (5.9%) Chronic pulmonary disease: 187 (17.8%) Arrhythmias: 177 (16.8%) Neurological disorders: 117 (11.1%) Diabetes mellitus: 343 (32.6%) **PSI class:** I: 0 II: 162 (15.4%) III: 342 (32.5%) IV: 394 (37.5%) V: 154 (14.6%) **CURB-65:** 0: 115 (10.9%) 1: 439 (41.7%) 2: 390 (37.1%) 3: 98 (9.3%) 4: 10 (1%) 5: 0 **CRB-65:** 0: 128 (12.6%) 1: 489 (48.1%) 2: 294 (28.9%) 3: 95 (9.4%) 4: 10 (1%)		***1*** ***2*** ***3 or 4*** ***Age (per year)*** ***Metastatic cancer*** ***Solid tumour without metastasis*** ***Stroke***	2.81 (1.82 to 4.32) 4.53 (2.57 to 7.99) 21.6 (5.14 to 90.82) 1.06 (1.04 to 1.08) 25.96 (8.13 to 82.95) 1.91 (1.14 to 3.19) 1.96 (1.32 to 2.90)		development and validation process. They suggested that external validation of the enhanced CURB score to other populations would be the next step.

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Capelastegui et al. 2006[13] **Study type:** Retrospective analysis of a prospective, consecutive cohort study **Selection / patient setting:** Galdakao teaching hospital, Basque Country, Spain Consecutive cohort of adults admitted to the ED of the Galdakao hospital with a diagnosis of CAP over a 4 year period. **Addressing missing data/non reliability of data:** all missing data or unperformed laboratory tests were considered to be normal. **Statistical analysis (including confounders adjusted for):** Frequencies, ROC analysis	**Diagnosis:** Pneumonia defined as CXR pulmonary infiltrates and clinical symptoms consistent with pneumonia (cough, dyspnoea, fever, and/or pleuritic chest pain) **Inclusion criteria:** Adults (≥ 18 years) with a diagnosis of CAP **Exclusion criteria:** • HIV-positive • Chronically immunosuppressed • Hospitalised in the previous 14 days **All patients,** N: 1776 Exclusions reasons: 2.9% had incomplete information on scores **Included** N: 1776 (as there was imputation of missing values) **Age, mean (SD):** 61.8 (20.5) **Age ≥ 65 years, n (%):** 973 (54.8) **Gender: male, n (%):** 1124 (6.33) **Nursing home patients, n (%):** 102 (5.7) **Comorbidities, n (%):** Neoplastic disease: 72 (4.1) Liver disease: 62 (3.5) Congestive heart failure: 101 (5.7) Cerebrovascular disease: 144 (8.1) Renal disease: 115 (6.5) **Pneumonia severity, n (%):** PSI I: 520 (29.3) PSI II: 287 (16.2) PSI III: 338 (19) PSI IV: 438 (24.7) PSI V: 193 (10.9) **LOS, mean (SD):** 5.1 (4.3)	• PSI (I to V) • CURB-65 (0 to 5) • CRB-65 (0 to 4)	• 30-day mortality: 119 (6.7%) • Mechanical ventilation: 18 (1%) ***Results*** AUC (95% CI) predicting 30-day mortality: • PSI: 0.888 (0.864-0.912) • CURB-65: 0.870 (0.844-0.895) • CRB-65: 0.864 (0.835-0.892)	**Funding:** NR **Limitations:** CURB-65 was not assessed as a tool for admission criteria **Additional outcomes**: **Notes**: the authors stated that the strength of the study was that it included bot inpatients and outpatients therefore it was possible to assess the utility of the CURB-65 in assisting the decision for hospital admission.

CURB-65 score	30-day mortality	Mechanical ventilation
0 (n = 699)	0	0
1 (n = 377)	4 (1.1%)	2 (0.5%)
2 (n = 474)	36 (7.6%)	9 (1.9%)
3 (n = 224)	47 (21%)	4 (2%)
4 (n = 62)	26 (41.9%)	2 (4.2%)
5 (n = 10)	6 (60%)	1 (11.1%)

CRB 65 score	30-day Mortality	Mechanical ventilation
0 (n = 716)	0	1 (0.1)
1 (n = 686)	28 (4.1%)	8 (1.2%)
2 (n = 294)	55 (18.7%)	6 (2.2%)
3 (n = 69)	30 (43.5%)	2 (3.9%)
4 (n = 11)	6 (54.6%)	1 (10%)

PSI score	30-day mortality
Low (I/II/III)(n = 1145)	0.7%
High (IV/V) (n = 631)	17.6%

CURB-65 score	30-day mortality
0-1 (n = 1006)	0.4%
2 (n = 474)	7.6%
> 2 (n = 296)	26.7%

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures	Comments
Author and year: Menendez 2009[34] **Study type:** Prospective longitudinal study **Selection / patient setting:** Patients with CAP consecutively hospitalised in two hospitals in Spain **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP was defined as new radiographic infiltrate and at least two compatible clinical symptoms consistent with pneumonia. **Inclusion criteria:** No further details were given. **Exclusion criteria:** • Admission to hospital within the previous 15 days • Immunosuppressive and/or glucocorticosteroid treatment, • leucopaenia < 1000/mm^3 • neutropaenia < 500/mm^3 • patients with do-not-resuscitate (DNR) orders. **All patients,** N: 480 Exclusions reasons: not given **Included** N: 453 **Age, mean (SD):** 67.3 (17.1) **Gender: male, n (%):** 282 (58.7%) **Long term care facility patients, n (%):** 24 (5.3%) **Comorbidities, n (%):** Heart failure: 76 (16.8) Renal failure: 25 (5.5) Diabetes: 91 (20.1) Liver disease: 12 (2.6) COPD: 79 (17.4)	• PSI (I to V) • CURB-65 (0 to 5) • CRB-65 (0 to 4)	• 30-day mortality: 36 (7.9%) ***Results*** AUC (95% CI) predicting 30-day mortality: • PSI: 0.81 (0.75-0.87) • CURB-65: 0.82 (0.76-0.89) • CRB-65: 0.79 (0.72-0.87) **PSI score** / **30-day Mortality** I (n = 48): 0 II (n = 73): 0 III (n = 95): 2 (2.1%) IV (n = 167): 14 (8.3%) V (n = 70): 20 (28.6%) **CURB 65 score** / **30-day Mortality** 0 (n = 64): 1 (1.5%) 1 (n = 141): 1 (0.1%) 2 (n = 130): 7 (5.4%) 3 (n = 79): 13 (16.5%) 4 (n = 33): 10(30.3%) 5 (n = 6): 4 (66.7%) **CRB 65 score** / **30-day Mortality** 0 (n = 79): 1 (1.2%) 1 (n = 193): 4 (2.1%) 2 (n = 126): 14 (11.1%)	**Funding:** BY CIBERES grant, TV3 TV040530 (grant for research not related to any industry) **Limitations:** outpatients with CAP were not included in the study **Additional outcomes**: **Notes**: the study was designed to test the diagnostic value of IL6, IL8, IL10, tumour necrosis factor α and the markers CRP and CPT.

Reference	Patient Characteristics	Risk Assessment tools (including thresholds used)	Outcomes measures		Comments
	Neurological disease: 98 (21.6) Neoplasm: 19 (4.1)		3 (n = 42)	13 (31%)	
			4 (n = 7)	4 (57.1%)	

Reference	Patient Characteristics	Risk Assessment tools at admission	Outcomes measures	Results	Comments
Author and year: Fukuyama et al. 2011[23] **Study type:** Prospective **Selection / patient setting:** Community hospital in Kurashiki City, Japan. Adults admitted to hospital with CAP diagnosis **Addressing missing data/non reliability of data:**.205 (40.6%) patients excluded from evaluation as no arterial blood gas data available **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP diagnosis based on clinical signs and symptoms of LRTI (fever, cough, purulent sputum) in addition to new CXR infiltrate **Inclusion criteria:** Patients with CAP diagnosis **Exclusion criteria:** • HAP, HCAP or VAP • Patients who develop comorbid conditions during follow-up **All patients,** N: 505 Exclusions reasons: NR **Included** N: 505 **Age, median (range):** 76 (67-83) **Gender: male, n (%):** 339 (67.13) **Nursing home patients, n (%):** excluded (HCAP) **Comorbidities, n (%):** Chronic pulmonary disease: 200 (39.6) Chronic heart disease: 126 (25.0) Cerebrovascular disease: 120 (23.8) Diabetes: 100 (19.8) Cancer: 47 (9.3) **Pneumonia severity:** NR **LOS, median (range):** 10 (7-18)	• SCAP (Espana rule) • PSI • A-DROP • CURB-65 • IDSA/ ATS • SMART-COP	•In-hospital mortality •ICU admission	e) In-hospital mortality , n (%); 33 (6.5) f) ICU admission, n (%): 32 (6.3) g) Predictive value of severity tools for in-hospital mortality h) Predictive value of severity tools for ICU admission	**Funding:** National health and medical research council of Australia **Limitations** • As only patients from one centre were included, the sample might not reflect the full patient population • HCAP was excluded as recent evidence indicates HCAP differs from CAP regarding pathogens and prognosis • The performance of severity scores was evaluated only in patients with full data. Low severity cases might have been excluded as patients without arterial blood gases information were excluded (arterial blood gases are usually not performed in patients without respiratory failure) **Additional outcomes**: Readmission within 30 days Recurrence **Notes:**

Severity tool	Sensitivity %	Specificity %	PPV %	NPV %
SCAP	96.7	35.4	14.4	99.0
PSI IV-V	93.3	31.3	13.2	97.7
A-DROP (3-5)	76.7	59.7	17.6	95.8
CURB-65 (3-5)	60.0	68.7	17.6	93.9
IDSA/ATS	86.7	61.9	20.3	97.6
SMART-COP	93.3	45.1	16.0	98.4

Severity tool	Sensitivity %	Specificity %	PPV %	NPV %
SCAP	93.5	35.2	14.4	97.9
PSI IV-V	93.5	31.5	13.7	97.7
A-DROP (3-5)	71.0	59.2	16.8	94.6
CURB-65 (3-5)	77.4	70.8	23.5	96.4
IDSA/ATS	93.5	62.9	22.7	98.8
SMART-COP	100	46.1	17.7	100

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Barlow et al. 2007[6] **Study type:** Retrospective **Selection / patient setting:** Two hospitals: a teaching hospital and a district general hospital in England, UK. Adults admitted to hospital with a diagnosis of CAP **Addressing missing data/non reliability of**	**Diagnosis:** CAP diagnosis by a specialist register or consultant doctor or had a new infiltrate on CXR **Inclusion criteria:** Patients were included if they were receiving antibiotics for a suspected LRTI and had either a new infiltrate on CXR or a clinical diagnosis by a specialist **Exclusion criteria:** Non-pneumonia diagnosis Aspiration, hypostatic pneumonia or HAP Initial diagnosis of CAP was changed before discharge from hospital HIV-positive, neutropenia	• CURB-65 • CRB-65 • SIRS • SEWS	30 day mortality	a) 30-day mortality , n (%); 13 (3) b) ICU admission, n (%): 79 (19) c) Predictive value of severity tools for 30-day mortality in CXR-confirmed cohort (218 patients)	**Funding:** The original study was funded by NHS Education Scotland **Limitations** • Patients were included using a pragmatic, real-life definition of CAP. However, subgroup analysis of CXR cohort confirmed the findings. • As urine output cannot be measured accurately on admission to hospital and

Severity	Mortality	Sensitivity	Specificity	PPV	NPV
CURB-65					
CURB-65 = 0	0/37 (0%)	100%	0%	14%	NC
CURB-65 = 1	1/48 (2%)	100%	20%	17%	100%
CURB-65 = 2	8/54 (15%)	97%	45%	22%	99%
CURB-65 = 3	10/51 (20%)	70%	69%	27%	93.5%
CURB-65 = 4	9/24 (37.5%)	23%	91%	29%	88%
CURB-65 = 5	2/4 (50%)	7%	99%	50%	87%
CRB-65					
CRB-65 = 0	0/47 (0%)	100%	0%	14%	NC
CRB-65 = 1	8/75 (11%)	100%	25%	17.5%	100%
CRB-65 = 2	10/62 (16%)	73%	61%	23%	93%
CRB-65 = 3	10/30 (33%)	40%	88%	35%	90%
CRB-65 = 4	2/4 (50%)	7%	99%	50%	87%
SIRS used in four different ways					
No SIRS[1]	10/62 (16%)	100%	0%	14%	NC
SIRS	5/110 (4.5%)	67%	28%	13%	84%
Severe sepsis/septic shock	15/46 (33%)	50%	83.5%	33%	91%
SIRS = 0[2]	4/18 (22%)	100%	0%	14%	NC

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results						Comments
data: 419 (83%) patients had full data for all the tools. **Statistical analysis (including confounders adjusted for):** ROC analysis	secondary to chronic illness or treatment or markedly immunosuppressed Progressive malignancy Chronic respiratory disease other than asthma or COPD Age < 16 years **All patients,** N: 503 Exclusions reasons: NR **Included** N: 503 (218 patients with CXR-confirmed pneumonia) **Age, median (range):** 74 (16-98) **Age > 65 years, n (%):** 292 (70%) **Gender: male, n (%):**			SIRS = 1	6/44 (14%)	87%	7%	13%	78%	would delay the assessment of severity, oliguria was also excluded as a criterion of hypoperfusion and was not scored in SEWS **Additional outcomes**: Analysis in the main cohort without confirmed CXR diagnosis **Notes:** Of the 503 included patients, 218 patients had CXR-confirmed
				SIRS = 2	9/67 (13%)	67%	28%	13%	84%	
				SIRS = 3	10/60 (17%)	37%	58.5%	12%	85%	
				SIRS = 4	1/29 (3%)	3%	85%	3%	85%	
				SIRS = 0[3]	4/18 (22%)	100%	0%	14%	NC	
				SIRS = 1	6/44 (14%)	87%	7%	13%	78%	
				SIRS = 2	2/47 (4%)	67%	28%	13%	84%	
				SIRS = 3	3/41 (7%)	60%	52%	16.5%	89%	
				SIRS = 4	0/22 (0%)	50%	72%	22%	90%	
				Severe sepsis/septic shock	15/46 (33%)	50%	83.5%	33%	91%	
				No SIRS or hypotension/ organ hypoperfusion	4/43 (9%)	100%	0%	14%	NC	
				SIRS	5/110 (4.5%)	87%	21%	15%	91%	
				Hypotension and/or organ hypo-perfusion, but no SIRS	6/19 (32%)	70%	77%	32%	94%	
				Severe sepsis/septic shock	15/46 (33%)	50%	83.5%	33%	91%	
				SEWS						
				SEWS = 0	2/23 (9%)	100%	0%	14%	NC	

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	197 (47) **Nursing home patients, n (%):** NR **Comorbidities, n (%):** NR **Pneumonia severity, n (%):** CURB-65 0 or 1:140 (33.5) CURB-65 2: 119 (28.5) CURB-65 ≥ 3: 160 (38) **LOS, median (range):** 5 (0-116)			SEWS = 1 | 3/29 (10%) | 93% | 11% | 14% | 91% SEWS = 2 | 6/39 (15%) | 83% | 25% | 15% | 90% SEWS = 3 | 3/39 (8%) | 63% | 42.5% | 15% | 62% SEWS = 4 | 3/33 (9%) | 53% | 62% | 18% | 89% SEWS = 5 | 4/23 (17%) | 43% | 78% | 24% | 90% SEWS ≥ 6 | 9/32 (28%) | 30% | 88% | 28% | 89% NC = Not calculable 1. Defined as in Table 1, main paper 2. Defined by presence or absence of: temperature < 36ºC or > 38ºC, pulse > 90/minute, respiratory rate > 20/minute and white cell count < 4 or > 12 cells per mm^3 3. Defined by above plus severe sepsis/septic shock d) AUC (95% CI) for 30 day mortality in the CXR-confirmed cohort (218 patients): • CURB-65: 0.79 (0.72-0.86) • CRS65:0.75 (0.67-0.83) • SIRS: 0.70 (0.59-0.81) • SEWS: 0.61 (0.49-0.72)	pneumonia

Reference	Patient Characteristics	Risk Assessment tools at admission	Outcomes measures	Results	Comments
Author and year: Shindo et al. 2008 [42] **Study type:** Retrospective **Selection / patient setting:** Community hospital in Handa, Japan. Patients admitted to hospital with a CAP diagnosis **Addressing missing data/non reliability of data:** 42 patients not evaluated due to lack of data on respiratory rate at hospital admission **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP defined as pneumonia in a patient who was not hospitalised and was carrying on with activities of daily living. **Inclusion criteria:** Patients with diagnosis of CAP, some patients with HCAP have been included (number not given) **Exclusion criteria:** HAP **All patients,** N: 329 Exclusions reasons: NR **Included** N: 329 **Age, mean (SD):** 75 (15.6) **Age ≥ 65 years, n (%):** 270 (82.1) **Gender: male, n (%):** 197 (59.9) **Nursing home patients, n (%):** 80 (24.3) **Comorbidities > 10%, n (%):** • Neoplastic disease: 42 (12.8) • Chronic pulmonary disease: 107 (32.5) • Chronic heart failure: 40 (12.2) • CNS disorder: 96 (29.2) • Diabetes: 57 (17.3) **Pneumonia severity:** NR **LOS, median (range):** 13 (1-157)	• A-DROP • CURB-65	•30-day mortality •ICU admission	a) 30-day mortality , n (%); 31 (9.4) b) ICU admission, n (%): 48 (14.6) c) AUC for 30-day mortality (95% CI), all patients: • A-DROP:0.846 (0.790-0.903) • CURB-65: 0.835 (0.763-0.908) d) AUC for 30-day mortality (95% CI), HCAP patients excluded: • A-DROP:0.910 (0.844-0.976) • CURB-65: 0.835 (0.835-0.988) e) 30-day mortality (%) in each risk class:	**Funding:** NR **Limitations** • Data was retrospectively collected from a single institution **Additional outcomes**: Readmission within 30 days Recurrence **Notes:** No info on number of patients with HCAP

Severity tool	30-day mortality, n (%)
A-DROP	
0	0 (0)
1	0 (0)
2	4.5 (4)
3	15.9 (11)
4	32.5 (13)
5	42.9 (3)
CURB-65	
0	0 (0)
1	1.5 (1)
2	3.9 (4)
3	9.8 (8)
4	42.9 (12)
5	42.9 (6)

Reference	Patient Characteristics	Risk assessment tools at admission	Outcomes measures	Results	Comments
Author and year: Brown et al. 2009[11] **Study type:** Retrospective **Selection / patient setting:** Academic tertiary hospital in Salt Lake City, USA. Patients with CAP admitted to the ED or directly admitted to hospital **Addressing missing data/non reliability of data:**. **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** Patients admitted within 72 h with ICD-9 code compatible with a primary diagnosis of pneumonia or respiratory failure or organism-specific sepsis with a secondary diagnosis of pneumonia. Admission CXR compatible with pneumonia also required **Inclusion criteria:** Patients with a diagnosis of pneumonia excluding HCAP/HAP **Exclusion criteria:** • Primary diagnosis of aspiration pneumonia • Nursing home residents • Patients discharged from hospital within 90 days • Patients receiving chronic haemodialysis, significant immunosuppression, present/past haematological malignancies • Patients with DNR/DNI orders at admission **All patients,** N: 3287 Exclusions reasons: Dialysis: 58, DNR/DNI: 333, Died in the ED: 5, HAP (discharged from hospital within 90 days): 435, Pneumonia in the past year: 96 [some patients had more than 1 exclusion reason] **Included** N: 2413 **Age:** 56.2 (not reported if mean or median) **Gender: male, (%):** (51.4) **Nursing home patients, n (%):** NR **Comorbidities, n (%):** NR **Pneumonia severity:** CURB-65 (points): 1.1 SMART-COP (points): 1.8 IDSA/ATS minor criteria (points): 1.1 **Bacteraemia (%):** 2.3 **LOS, median (range):** NR	• CURB-65 • IDSA/ATS • SMART-COP	• SCAP (severe CAP): receipt of intensive therapy in the ICU	a) 30-day mortality , n (%); 89 (3.7) b) ICU admission, n (%): 378 (25) c) AUC for prediction of SCAP as defined in the previous column: • IDSA/ATS: 0.88 (0.85-0.90) • SMART-COP: 0.83 (0.80-0.86) • CURB-65: 0.76 (0.73-0.80)	**Funding:** National health and medical research council of Australia **Limitations** • Retrospective analysis relying on ICD-9 coding rather than prospective screening **Additional outcomes**: CURXO-80 **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Kohno et al. 2013[28] **Study type:** Prospective **Selection / patient setting:** Multicentre observational cohort study, including 128 general hospitals and 7 university hospitals in Japan. Patients ≥20 years admitted to hospital with respiratory failure (without mechanical ventilation) due to CAP **Addressing missing data/non reliability of**	**Diagnosis:** CAP was defined as pneumonia which developed acutely without a history of hospitalization or admission to long-term care facilities within 2 weeks of onset, acute infiltrates on CXR, leukocytosis, increased band cells, leukopaenia or elevated CRP, fever, respiratory symptoms or at least one abnormal finding on phonacoscopy. clinical signs and symptoms of LRTI (fever, cough, purulent sputum) in addition to new infiltrate on CXR **Inclusion criteria:** Patients with a diagnosis of CAP and acute respiratory failure **Exclusion criteria:** Non-infectious pneumonia, including interstitial pneumonia,	• PSI • A-DROP: 0 = mild 1 or 2 = moderate 3 = severe 4 or 5 = extremely severe	• 28-day mortality • ICU admission	a) 28-day mortality , n (%); 58 (12.3) b) ICU admission, n (%): 41 (8.7) c) AUC of severity tools for 28-day mortality (95% CI): • A-DROP: 0.6721 (0.5983-0.7458) • PSI: 0.6324 (0.5587-0.7061)	**Funding:** NR **Limitations** • Patients with aspiration pneumonia and HCAP were not excluded. Therefore studies that exclude these patients are required to confirm these results. • Similarly, studies that include patients without acute respiratory failure and outpatients will be required **Additional outcomes**: Requirement for mechanical ventilation No significant relationship was found between ICU admission rate and the severity of A-DROP) **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
data:.NR **Statistical analysis (including confounders adjusted for):** ROC analysis	pulmonary tuberculosis, organizing pneumonia and radiation pneumonitis, or patients with lung cancer. HAP (≥ 48 h of hospitalisation) **All patients,** N: 482 Exclusions reasons: NR **Included** N: 482 **Age, mean (SD):** 76.3 (12.0) **Gender: male, n (%):** 353 (73.2) **Nursing home patients, n (%):** NR **Comorbidities, n (%):** COPD: 126 (26.1) Asthma: 61 (12.7) **Pneumonia severity:** NR **LOS, median (range):** NR				

Reference	Patient Characteristics (based on the number of episodes, not patients)	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Chalmers et al. 2008 [15] **Study type:** Prospective **Selection / patient setting:** Patients with CAP at the NHS Lothian University Hospitals in Edinburgh, UK **Addressing missing data/non reliability of data:** There were no missing data in the study **Statistical analysis (including confounders**	**Diagnosis:** CAP diagnosis was based on new infiltrate on CXR and at least 3 of the following symptoms: cough, sputum, breathlessness, pleuritic chest pain, haemoptysis, fever, headache, and signs consistent with pneumonia on chest auscultation. **Inclusion criteria:** Age < 50 years and CAP diagnosis (see above) **Exclusion criteria:** HAP, active thoracic malignancy, immunosuppression, pulmonary embolism, and patients for whom active treatment was not considered to be appropriate (those in palliative care)	• PSI • CURB-65 • SMART-COP	• Need for intensive respiratory or vasopressor support (IRVS)	a) IRVS required: n (%): 33 (9.9) b) 30-day mortality , n (%); 5 (1.5) c) Prediction of IRVS requirement by assessment tools:	**Funding:** JD Chalmers was supported by a Clinical research training fellowship from the Medical Research Council **Limitations:** NR **Additional outcomes**: **Notes:** Younger patients [All of the patients who died within 30 days had at least 1 comorbidity. Because of the low mortality rate, analysis of the severity scores was limited to the primary outcome of

Severity tool	Sensitivity %	Specificity %	PPV %	NPV %	AUC (95% CI)
PSI ≥ IV	54.5	82.8	25.7	94.3	0.80 (0.75-0.84)
CURB-65 ≥ 3	54.5	89.6	34.0	95.2	0.81 (0.76-0.86)
SMART-COP > 2	84.8	82.1	34.1	98.0	0.87 (0.83-0.91)

Reference	Patient Characteristics (based on the number of episodes, not patients)	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
adjusted for): ROC analysis	**All patients** Number of patients: 335 Exclusions reasons: NR **Included** N: 335 **Age, median (range):** 36 (28-43) **Gender: male, n (%):** NR **Nursing home patients, n (%):** NR **Comorbidities (>5%), n (%):** Chronic liver disease: 31 (9.2) [Prevalence of other comorbidities <5%] **Pneumonia severity:** NR **LOS, median (range):** NR				requirement of mechanical ventilation and/or inotropic support]

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Salluh et al. 2008[39] **Study type:** Prospective **Selection / patient setting:** One tertiary hospital in Rio de Janeiro, Brazil. Consecutive patients with CAP requiring ICU admission **Addressing missing data/non reliability of data:** NR **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP severity was assessed by the presence of acute organ dysfunctions and CURB-65. **Inclusion criteria:** Patients with CAP requiring ICU admission **Exclusion criteria:** Patients who had received steroids in the ED and within the previous year **All patients,** N: 99 Exclusions reasons: • Glucocorticosteroids used in the ED: 20 • Previously used glucocorticosteroids: 7 **Included** N: 72 **Age, median (range):** 71 (52.5-83.7) **Gender: male, n (%): 34** (47.2) **Nursing home patients, n (%):** NR **Comorbidities, n (%):** COPD: 7 (9.7) **Pneumonia severity, median (range):** • APACHE II: 14 (11-17) • CURB-65: 3 (3-4) **LOS, median (range):** 10 (7-18.5)	• CURB-65 • APACHE-II • SOFA	Hospital mortality	a) Hospital mortality , n (%); 12 (16.7) b) Predictive value of CURB-65 and APACHE II for hospital mortality **CURB-65** 2.5 / 25 / 100 / NR 3.5 / 56.6 / 75 / 2.27 4.5 / 88.3 / 33.3 / 1.32 **APACHE II** 12.5 / 91.6 / 38.3 / 1.49 14.5 / 66.6 / 60 / 1.67 22 / 33.3 / 96.6 / 10 c) AUC for hospital mortality: • CURB-65: 0.71 (0.57-0.86) • APACHE II: 0.71 (0.56-0.86) • SOFA: 0.62 (0.41-0.84)	**Funding:** NR **Limitations** • Exclusion of patients who had used corticosteroids limited the population, therefore results may not be generalizable • Single-centre study • Small sample of severe patients, which may have affected the lack of statistical significance of AUC of CURB-65 and APACHE II **Additional outcomes**: **Notes:** Population of severe patients

Reference	Patient Characteristics	Risk Assessment tools at hospital admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Yang et al. 2012[48] **Study type:** Retrospective **Selection / patient setting:** One university hospital in China. Adults with CAP admitted to hospital. **Addressing missing data/non reliability of data:** NR **Statistical analysis (including**	**Diagnosis:** CAP diagnosis was based on the presence of infiltrates on CXR, respiratory symptoms with or without pleuritic chest pain, fever, signs of consolidation of lung tissue, and/or the presence of crackling sounds and high WBC count **Inclusion criteria:** Patients with CAP (as described above) **Exclusion criteria:** Lung tumour, non-infective interstitial lung diseases, pulmonary oedema, pulmonary embolism, or pulmonary infiltration with eosinophilia and lung vasculitis	• PSI • CURB-65 • Sepsis score	• 30-day mortality	a) 30-day mortality, n (%): 71 (10.5) b) AUC for 30-day mortality: • PSI: 0.94 • CURB-65: 0.91 • Sepsis score: 0.89 c) Mortality (%) according to severity class:	**Funding:** NR **Limitations:** • Retrospective study • Single centre study **Additional outcomes**:

Severity tool	30-day mortality % (n dead/total n patients)
PSI	
I-III (low risk)	0.7 (3/461)
IV-V (high risk)	31.8 (68/214)
CURB-65	
0-1 (low risk)	2.5 (13/517)
2 (moderate risk)	14.6 (12/82)
3-5 (high risk)	60.5 (46/76)
Sepsis score	
non-sepsis (low risk)	0.4 (1/247)
sepsis (intermediate risk)	4.8 (16/332)
severe sepsis and septic shock (high risk)	56.2 (54/96)

Reference	Patient Characteristics	Risk Assessment tools at hospital admission (including thresholds used)	Outcomes measures	Results	Comments
confounders adjusted for): ROC analysis	**All patients,** N: 675 Exclusions reasons: NR **Included** N: 675 **Age, mean (SD):** 61.1 (18.1) **Gender: male, n (%):** 428 (63.4) **Nursing home patients, n (%):** NR **Comorbidities (> 10%), n (%):** • Chronic lung disease: 78 (11.6) • Chronic heart disease: 71 (10.5) • Diabetes: 71 (10.5) **Pneumonia severity:** NR **LOS, median (range):** NR				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Ribeiro et al. 2013[37] **Study type:** Retrospective **Selection / patient setting:** Patients admitted to hospital with pneumococcal pneumonia **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP was diagnosed based on new infiltrate on CXR with symptoms and signs of acute respiratory illness, and positive for S. pneumoniae. **Inclusion criteria:** Patients with CAP due to S. pneumoniae. **Exclusion criteria:** NR **All patients,** N: 142 Exclusions reasons: NR **Included** N: 142 **Age, mean (SD):** 58.7 (16.9) **Gender: male (%):** 54.2% **Nursing home patients:** NR **Comorbidities: NR** **Pneumonia severity:** **PSI low** 93 (65.5%)	• CURB65 • PSI • SCAP • SMART-COP	• Mortality • Need for ICU admission	• Mortality, n (%): 2 (1.4) • Need for ICU admission, n (%): 22 (15.5) **Score / Mortality / Need for ITU admission** **PSI low**: 0 (0) / 10 (10.8%) **PSI medium**: 0 (0) / 8 (21.6%) **PSI high**: 2 (16.7%) / 4 (33.3%) **CURB65 low**: 0 (0) / 8 (8.3%) **CURB65 medium**: 0 (0) / 9 (28.1%) **CURB65 high**: 2 (15.4%) / 5 (38.5%) **SCAP low**: 0 (0) / 2 (2.8%) **SCAP medium**: 0 (0) / 8 (14.6%) **SCAP high**: 2 (13.3%) / 12 (80%) **SMART-COP low**: 0 (0) / 4 (4.2%) **SMART-COP medium**: 1 (2.8%) / 7 (19.4%) **SMART-COP high**: 1 (9.1%) / 11 (100%) • Predictive value for mortality: **Score / Sensitivity / Specificity / NPV / AUC (95% CI)** PSI > III: 1 / 0.66 / 1 / 0.96 (0.92-1) CURB65 > 1: 1 / 0.69 / 1 / 0.96 (0.92-1) SCAP > 10: 1 / 0.51 / 1 / 0.95 (0.91-1) SMART-COP > 2: 1 / 0.68 / 1 / 0.88 (0.74-1)	**Funding:** NR **Limitations** • Population limited to patients with pneumococcal pneumonia • Retrospective design **Additional outcomes**: **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	PSI medium 37 (26.1%) **PSI high** 12 (8.4%) **CURB65 low** 97 (68.3%) **CURB65 medium** 32 (22.5%) **CURB65 high** 13 (9.2%) **SCAP low** 72 (50.7%) **SCAP medium** 55 (38.7%) **SCAP high** 15 (10.6%) **SMART-COP low** 95 (66.9%) **SMART-COP medium** 36 (25.3%) **SMART-COP high** 11 (7.8%) **LOS, mean (SD):** 13.9 (9.9)			• Predictive value for ITU admission: **Score** / **Sensitivity** / **Specificity** / **NPV** / **AUC (95% CI)** PSI > III / 0.55 / 0.69 / 0.89 / 0.62 (0.49-0.76) CURB65 > 1 / 0.64 / 0.74 / 0.92 / 0.70 (0.57-0.82) SCAP > 10 / 0.91 / 0.58 / 0.97 / 0.85 (0.75-0.95) SMART-COP > 2 / 0.82 / 0.76 / 0.96 / 0.85 (0.74-0.96)	

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Xiao et al. 2013[47] **Study type:** Retrospective **Selection / patient setting:** Consecutive patients with CAP admitted to ICU in a general hospital in China **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP was diagnosed based on new infiltrate on CXR with symptoms and signs of a LRTI in a patient who was not hospitalised or in a healthcare facility in the previous 14 days **Inclusion criteria:** Patients aged ≥ 65 years with a diagnosis of CAP as defined above. **Exclusion criteria:** • Age < 65 • Evidence of HAP, or admitted to the hospital in the previous 14 days, and onset of pneumonia symptoms beyond 48 h after admission • Infiltrate on CXR followed by obstructive pneumonia resulting from malignancy, pulmonary oedema, pulmonary embolism, or non-infectious pneumonia • Patients with severe immunosuppression and taking immune-suppressing drugs. **All patients,** N: 240 Exclusions reasons: NR	• CURB65 • PSI • APACHE II	28-day mortality	AUC for 28-day mortality in ICU patients: • CURB65: 0.810 • PSI: 0.868 • APACHE II: 0.860	**Funding:** NR **Limitations** • Study focused on elderly patients with high comorbidity burden • Retrospective design **Additional outcomes**: **Notes:** All patients were treated with standard antibiotic therapy according to BTS guidelines

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	Included N: 240 **Age, mean (SD):** 75 (8) **Gender: male (%):** 59.6 **Nursing home patients:** excluded **Comorbidities > 10%, n (%):** • Cerebrovascular disease: 50 (20) • COPD: 84 (35) • Cardiac functional insufficiency: 51 (21) • Diabetes: 67 (28) • CKD: 35 (14.5) **Pneumonia severity – survivor/non-survivor:** • CURB65: 2/3 • PSI: 104/151 • APACHE II: 13/22 **LOS in ICU, mean (range) – survivor/non-survivor:** 15 (10-22)/11 (7-15)				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Dwyer et al. 2011[19] **Study type:** Retrospective **Selection / patient setting:** Patients with bacteriaemic pneumococcal CAP prospectively recruited in a previous multicentre study in 3 hospitals in Sweden **Addressing missing data/non reliability of data:** **Statistical**	**Diagnosis:** CAP was diagnosed based on new infiltrate on CXR and pneumococcal bacteraemia **Inclusion criteria:** Patients aged ≥18 years with a diagnosis of CAP and pneumococcal bacteriaemia as defined above. **Exclusion criteria:** • Patients admitted to hospital in the previous month **All patients,** N: 375 Exclusions reasons: NR **Included** N: 375 **Age, median (range):** survivors – 62.0 (18-98), non-survivors – 75 (38-93 **Gender: female (%):** 49.6 **Nursing home patients:** 3.2% **Comorbidities > 10%, n (%):**	• CURB65 • PSI • CRB65	30-day mortality	30-day mortality n (%): 35 (9) AUC for 30-day mortality: • PSI: 0.84 • CURB65: 0.81 • CRB65: 0.77 **PSI score** / **30-day Mortality, n (%)** I (n = 48): 0 II (n = 68): 0 III (n = 75): 4 (5) IV (n = 117): 6 (5) V (n = 67): 25 (37) **CURB 65 score** / **30-day Mortality, n (%)** 0 (n = 87): 0 1 (n = 111): 6 (5) 2 (n = 100): 6 (6) 3 (n = 56): 12 (21) 4 (n = 19): 9 (47) 5 (n = 2): 2 (100) **CRB 65 score** / **30-day Mortality, n (%)** 0 (n = 97): 3 (3) 1 (n = 140): 6 (4) 2 (n = 100): 10 (10)	**Funding:** NR **Limitations** • Only patients with bacteraemic pneumococcal pneumonia were included • Retrospective design • Serum creatinine was used instead of serum urea for PSI and CURB65 **Additional outcomes**: **Notes:** All patients were treated with standard antibiotic therapy according to BTS guidelines

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
analysis (including confounders adjusted for): ROC analysis	• Any cardiac disease: 112 (30) • Pulmonary disease: 64 (17) **LOS in ITU, mean (range) – survivor/non-survivor:** 15 (10-22)/11 (7-15)			3 (n = 36) | 14 (39) 4 (n = 2) | 2 (100)	

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Chalmers et al. 2011 [16] **Study type:** Prospective study **Selection / patient setting:** Unselected patients with CAP admitted to NHS Lothian hospitals in Scotland, UK **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP was diagnosed based on new infiltrate on CXR and three or more symptoms and sign consistent with pneumonia **Inclusion criteria:** Patients with a diagnosis of CAP as defined above. **Exclusion criteria:** • HAP • Radiographic changes due to lung cancer rather than pneumonia • Patients with systemic immunosuppression, HIV-infection, solid organ transplant, or pulmonary tuberculosis • Patients requiring mechanical ventilation/vasopressor support in the emergency department, or patients with do-not-attempt-resuscitation orders **All patients,** N: 1062 Exclusions reasons: NR **Included** N: 1062 **Age, median (range):** 63 (47-74)	• IDSA/ATS minor criteria • PSI • CURB65 • CRB65 • SMART-COP • SCAP • ATS minor criteria 2001	• 30-day mortality • ICU admission	30-day mortality, n (%): 48 (4.5) AUC (95% CI) for predicting ICU admission: • IDSA/ATS minor criteria: 0.85 (0.82 to 0.85) • PSI: 0.74 (0.71 to 0.77) • CURB65: 0.74 (0.71 to 0.78) • CRB65: 0.73 (0.69 to 0.76) • SMART-COP: 0.85 (0.83 to 0.88) • SCAP: 0.75 (0.72 to 0.78) • ATS minor criteria 2001: 0.70 (0.67 to 0.73) AUC (95% CI) for predicting 30-day mortality: • IDSA/ATS minor criteria: 0.78 (0.74 to 0.82) • PSI: 0.81 (0.78 to 0.85) • CURB65: 0.74 (0.70 to 0.78) • CRB65: 0.73 (0.68 to 0.77) • SMART-COP: 0.79 (0.75 to 0.83) • SCAP: 0.74 (0.70 to 0.78) • ATS minor criteria 2001: 0.68 (0.63 to 0.72)	**Funding:** Medical research council, UK **Limitations** • Study focused on patients without major criteria for ICU admission but who were eligible to ICU admission if required **Additional outcomes**: Predictive value of individual components of IDSA/ATS criteria **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	Gender: male (%): 48.3 **Nursing home patients:** NR **Comorbidities > 10%, n (%):** None > 10% **Pneumonia severity , mean (SD)** • CURB65: 1.7 (1.58) • PSI: 3.0 (1.52) **LOS, median days:** 5 (2- 10)				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Kasamatsu et al. 2012[26] **Study type:** Prospective study **Selection / patient setting:** Adult patients with CAP admitted to two Japanese hospitals **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** NR **Inclusion criteria:** Adult patients with a diagnosis of CAP **Exclusion criteria:** • Patients with mild CAP • Patients with moderate CAP who refused continuous hospitalisation • Immunosuppressed patients who were receiving chemotherapy or immunosuppressant therapy • Patients who could not be followed up or with diagnosis suspected to be inaccurate **All patients,** N: 226 Exclusions reasons: incomplete data **Included** N: 170 **Age, mean (SD):** 67.9 (18.1) **Gender: male (%):** 57.6 **Nursing home patients:** NR **Comorbidities > 10%, n (%):** • Cerebrovascular disease: 26 (15.3) • COPD: 26 (15.3)	• A-DROP • CURB65 • PSI	• 30-day mortality	30-day mortality, n (%): 20 (11.8) AUC (95% CI) for predicting 30-day mortality: • A-DROP: 0.88 (0.82 to 0.94) • CURB65: 0.88 (0.82 to 0.94) • PSI: 0.89 (0.85 to 0.94)	**Funding:** NR **Limitations** • Only patients with moderate to severe CAP included • Criteria for hospitalisation differed from those used in other countries, depending on the physician's subjective assessment of the severity of dehydration **Additional outcomes**: **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	Pneumonia severity , n patients: • A-DROP 3-5 (severe): 57 • CURB65 3-5 (severe): 61 • PSI IV-V (severe): 96 **LOS, median days:** NR				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Robins-Browne et al. 2012[38] **Study type:** Prospective study **Selection / patient setting:** Patients with CAP admitted via ED to a tertiary hospital in Australia **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP was diagnosed based on new infiltrate on CXR or CT scan, and two or more symptoms and sign consistent with pneumonia **Inclusion criteria:** Adults aged > 18 years with a diagnosis of CAP as defined above. **Exclusion criteria:** • Aspiration pneumonia • Immunosuppression • Active orders limiting life-sustaining treatment • Hospitalisation for more than 48 hours prior to hospital admission or within the last 14 days, or direct admission to ICU **All patients,** N: 367 Exclusions reasons: NR **Included** N: 367 **Age, mean (IQR):** (47-74) **Gender: male (%):** 52% **Nursing home patients:** NR	• SMART-COP • PSI • CORB	• 30-day mortality • IRVS (intensive respiratory or vasopressor support) requirement	30-day mortality, n (%): 10 (3) **Severity tool** / **IRVS, n (%)** / **30-day mortality, n (%)** **SMART-COP** 0-2: 1 (0.4) / 1 (0.4) 3-4: 18 (20) / 3 (3.2) ≥ 5: 18 (44) / 6 (15) **PSI** I-II: 8 (4) / 1 (0.5) III: 5 (6) / 1 (1.1) ≥ IV: 24 (31) / 8 (10) **CORB** 0-1: 25 (7.5) / 5 (1.5) ≥ 2: 12 (36) / 5 (15) AUC (95% CI) for predicting IRVS: • SMART-COP ≥ 3: 0.89 (0.86 to 0.93) • PSI ≥ IV: 0.76 (0.68 to 0.85) • CORB ≥ 2: 0.69 (0.60 to 0.78)	**Funding:** NR **Limitations** • Study conducted in a single centre • Only 36% of pneumonia presentations were prospectively identified and enrolled by ED staff, which could have limited the number enrolled **Additional outcomes**: **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	Comorbidities > 10%, n (%): • COPD: 108 (29.4) • Diabetes: 73 (19.9) **Pneumonia severity, n (%)** • SMART-COP ≥ 5: 41 (11.2) • PSI ≥ IV: 78 (21.2) • CORB ≥2: 33 (9.0) **LOS:** NR				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Chen et al. 2010[18] **Study type:** Prospective study **Selection / patient setting:** Patients with CAP admitted via ED to a university hospital in Taiwan **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP was diagnosed based on new infiltrate on CXR and symptoms and sign consistent with pneumonia **Inclusion criteria:** Adults aged > 18 years with a diagnosis of CAP as defined above. **Exclusion criteria:** • HAP (development of pneumonia > 48 hours after hospital admission) **All patients,** N: 987 Exclusions reasons: NR **Included** N: 987 **Age- stratified as:** • younger adults, 18 to 64 years (348) • elderly, 65 to 84 years (438) • very old, ≥ 85 years (201) **Gender: male (%):** 61.9 **Nursing home patients:** NR **Comorbidities > 10%, n (%):** • Diabetes: 181 (18.3) • Cerebrovascular event: 121 (12.2)	• PSI • CURB65	• 30-day mortality	30-day mortality, n (%): 68 (6.8) **Severity tool** / **30-day mortality, n (%)** / **AUC (95% CI) for 30-day mortality** **PSI** I-II: 1 (0.4) III: 1 (0.5) ≥ IV: 66 (12.5) AUC: 0.83 (0.78 to 0.87) **CURB65** 0-1: 12 (2.4) 2: 23 (7.8) 3-5: 33 (16.6) AUC: 0.73 (0.67 to 0.79)	**Funding:** NR **Limitations** • Study conducted in a single centre **Additional outcomes**: subgroup analyses by age group **Notes:**

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
	• COPD: 140 (14.2) • Heart failure: 129 (13.0) • Non-haematogenous malignancies: 151 (15.3) **Pneumonia severity, mean** • Elderly/very old, PSI: 4, CURB65: 2 • Younger adults, PSI: 2, CURB65: 0 **LOS, days:** • Elderly: 8 (1 to 16) • Very old: 9 (2 to 17) • Younger adults: 1 (0 to 10)				

Reference	Patient Characteristics	Risk Assessment tools at admission (including thresholds used)	Outcomes measures	Results	Comments
Author and year: Schuetz et al 2010/2011[40,41] **Study type:** Prospective study **Selection / patient setting:** Patients with CAP enrolled in the multicentre ProHOSP study in Switzerland **Addressing missing data/non reliability of data:** **Statistical analysis (including confounders adjusted for):** ROC analysis	**Diagnosis:** CAP was diagnosed based on new infiltrate on CXR **Inclusion criteria:** Adults aged > 18 years with a diagnosis of CAP as defined above. **Exclusion criteria:** • Patients with dementia, immunosuppression, concomitant infections and active IV drug abuse **All patients,** N: 925 Exclusions reasons: NR **Included** N: 925 **Age, median (range):** 73 (58-82) **Gender: male (%):** 59 **Nursing home patients:** NR **Comorbidities > 10%, n (%):** • Chronic heart failure: 159 (17) • Renal failure: 206 (22) • COPD: 282 (30) **Pneumonia severity, n (%)** • PSI ≥IV: 473 (51.1) • CURB65 ≥3: 160 (17) **LOS, days, median (range):** 8 (5-13)	• PSI • CURB65	• 30-day mortality • ICU admission	30-day mortality (5.4%) **Severity tool** / **30-day mortality, n (%)** / **AUC (95% CI) for 30-day mortality** **PSI** I-II: 0 — 0.79 (0.75 to 0.84) III: 1 (0.6) ≥ IV: 49 (9.7) **CURB65** 0-1: 4 (0.9) — 0.72 (0.65 to 0.78) 2: 25 (8.4) 3-5: 21 (10.4) ICU admission (9.0%) **AUC (95% CI) for ICU admission:** • PSI: 0.65 (0.59 to 0.71) • CURB65: 0.64 (0.58 to 0.70)	**Funding:** NR **Limitations** • Exclusion of patients with dementia, immunosuppression, concomitant infections and active IV drug abuse may limit generabisability • Indications for ICU admission may vary between physicians, hospitals and countries **Additional outcomes**: **Notes:** Main focus of the study was the evaluation of PCT as a prognostic marker

2 References

1 Abisheganaden J, Ding YY, Chong WF, Heng BH, Lim TK. Predicting mortality among older adults hospitalized for community-acquired pneumonia: an enhanced confusion, urea, respiratory rate and blood pressure score compared with pneumonia severity index. Respirology. 2012; 17(6):969-975

2 Alavi-Moghaddam M, Bakhshi H, Rezaei B, Khashayar P. Pneumonia severity index compared to CURB-65 in predicting the outcome of community acquired pneumonia among patients referred to an Iranian emergency department: a prospective survey. Brazilian Journal of Infectious Diseases. 2013; 17(2):179-183

3 Ananda-Rajah MR, Charles PGP, Melvani S, Burrell LL, Johnson PDR, Grayson ML. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scandinavian Journal of Infectious Diseases. 2008; 40(4):293-300

4 Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. American Journal of Respiratory and Critical Care Medicine. 2002; 166(5):717-723

5 Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. American Journal of Medicine. 2005; 118(4):384-392

6 Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax. 2007; 62(3):253-259

7 Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ study group. CRB-65 predicts death from community-acquired pneumonia. Journal of Internal Medicine. 2006; 260(1):93-101

8 Belkhouja K, Ben Romdhane K, Ghariani A, Hammami A, M'hiri E, Slim-Saidi L et al. Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU. Journal of Infection and Chemotherapy. 2012; 18(3):324-331

9 Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz MA, Vera E et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. European Respiratory Journal. 2012; 39(5):1144-1155

10 Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJ. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Archives of Internal Medicine. 2008; 168(13):1465-1468

11 Brown SM, Jones BE, Jephson AR, Dean NC, Infectious Disease Society of America/American Thoracic Society. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Critical Care Medicine. 2009; 37(12):3010-3016

12 Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006; 61(5):419-424

13 Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M et al. Validation of a predictive rule for the management of community-acquired pneumonia. European Respiratory Journal. 2006; 27(1):151-157

14 Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax. 2008; 63(8):698-702

15 Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clinical Infectious Diseases. 2008; 47(12):1571-1574

16 Chalmers JD, Taylor JK, Mandal P, Choudhury G, Singanayagam A, Akram AR et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clinical Infectious Diseases. 2011; 53(6):503-511

17 Chang CL, Mills GD, Karalus NC, Jennings LC, Laing R, Murdoch DR et al. Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults. PloS One. 2013; 8(5):e62612

18 Chen JH, Chang SS, Liu JJ, Chan RC, Wu JY, Wang WC et al. Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects. Thorax. 2010; 65(11):971-977

19 Dwyer R, Hedlund J, Darenberg J, Henriques-Normark B, Naucler P, Runesdotter S et al. Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia. Scandinavian Journal of Infectious Diseases. 2011; 43(6-7):448-455

20 Ewig S, de Roux A, Bauer T, Garcia E, Mensa J, Niederman M et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax. 2004; 59(5):421-427

21 Feldman C, Alanee S, Yu VL, Richards GA, Ortqvist A, Rello J et al. Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care. Clinical Microbiology and Infection. 2009; 15(9):850-857

22 Francis NA, Cals JW, Butler CC, Hood K, Verheij T, Little P et al. Severity assessment for lower respiratory tract infections: potential use and validity of the CRB-65 in primary care. Primary Care Respiratory Journal. 2012; 21(1):65-70

23 Fukuyama H, Ishida T, Tachibana H, Nakagawa H, Iwasaku M, Saigusa M et al. Validation of scoring systems for predicting severe community-acquired pneumonia. Internal Medicine. 2011; 50(18):1917-1922

24 Guo Q, Li HY, Zhou YP, Li M, Chen XK, Liu H et al. CURB-65 score predicted mortality in community-acquired pneumonia better than IDSA/ATS minor criteria in a low-mortality-rate setting. European Journal of Clinical Microbiology and Infectious Diseases. 2012; 31(12):3281-3286

25 Jeong KY, Kim K, Kim TY, Lee CC, Jo SO, Rhee JE et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emergency Medicine Journal. 2011; 28(2):122-127

26 Kasamatsu Y, Yamaguchi T, Kawaguchi T, Tanaka N, Oka H, Nakamura T et al. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting

mortality among adults hospitalized with community-acquired pneumonia. Respirology. 2012; 17(2):330-336

27 Kim HI, Kim SW, Chang HH, Cha SI, Lee JH, Ki HK et al. Mortality of community-acquired pneumonia in Korea: assessed with the pneumonia severity index and the CURB-65 score

Are the Pneumonia Severity Index (PSI) and CURB-65 suitable in very old patients hospitalized with pneumonia? Journal of Korean Medical Science. 2013; 28(9):1276-1282

28 Kohno S, Seki M, Takehara K, Yamada Y, Kubo K, Ishizaka A et al. Prediction of requirement for mechanical ventilation in community-acquired pneumonia with acute respiratory failure: a multicenter prospective study. Respiration; International Review of Thoracic Diseases. 2013; 85(1):27-35

29 Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. American Journal of Emergency Medicine. 2009; 27(8):968-974

30 Lee JH, Chung HJ, Kim K, Jo YH, Rhee JE, Kim YJ et al. Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia. American Journal of Emergency Medicine. 2013; 31(1):72-79

31 Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piner R et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clinical Infectious Diseases. 2009; 48(4):377-385

32 Luque S, Gea J, Saballs P, Ferrandez O, Berenguer N, Grau S. Prospective comparison of severity scores for predicting mortality in community-acquired pneumonia. Revista Espanola De Quimioterapia. 2012; 25(2):147-154

33 Man SY, Lee N, Ip M, Antonio GE, Chau SSL, Mak P et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax. 2007; 62(4):348-353

34 Menendez R, Martinez R, Reyes S, Mensa J, Polverino E, Filella X et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax. 2009; 64(11):987-992

35 Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Ramos F, de Diego C, Salsench E et al. Comparison of three predictive rules for assessing severity in elderly patients with CAP. International Journal of Clinical Practice. 2011; 65(11):1165-1172

36 Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. 2009; 64(7):598-603

37 Ribeiro C, Ladeira I, Gaio AR, Brito MC. Pneumococcal pneumonia - Are the new severity scores more accurate in predicting adverse outcomes? Revista Portuguesa De Pneumologia. 2013; 19(6):252-259

38 Robins-Browne KL, Cheng AC, Thomas KAS, Palmer DJ, Currie BJ, Davis JS. The SMART-COP score performs well for pneumonia risk stratification in Australia's Tropical Northern Territory: a prospective cohort study. Tropical Medicine and International Health. 2012; 17(7):914-919

39 Salluh JIF, Bozza FA, Soares M, Verdeal JC, Castro-Faria-Neto HC, Lapa e Silva JR et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 2008; 134(5):947-954

40 Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B et al. Prognostic value of procalcitonin in community-acquired pneumonia. European Respiratory Journal. 2011; 37(2):384-392

41 Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Critical Care. 2010; 14(3):R106

42 Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K et al. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology. 2008; 13(5):731-735

43 Spindler C, Ortqvist A. Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. European Respiratory Journal. 2006; 28(4):816-823

44 Tejera A, Santolaria F, Diez ML, Aleman-Valls MR, Gonzalez-Reimers E, Martinez-Riera A et al. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine. 2007; 38(3):117-123

45 Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agusti C, Angrill J et al. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest. 2007; 132(2):515-522

46 Varshochi M, Kianmehr P, Naghavi-Behzad M, Bayat-Makoo Z. Correspondence between hospital admission and the pneumonia severity index (PSI), CURB 65 criteria and comparison of their predictive value in mortality and hospital stay. Le Infezioni in Medicina. 2013; 21(2):103-110

47 Xiao K, Su Lx, Han BC, Yan P, Yuan N, Deng J et al. Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study. Journal of Thoracic Disease. 2013; 5(5):626-633

48 Yang Y, Xu F, Shi LY, Diao R, Cheng YS, Chen XY et al. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China. Chinese Medical Journal. 2012; 125(4):639-645

49 Zuberi FF, Khan JA. Prospective comparison of prediction rules of mortality risk for CAP in a developing country. International Journal of Tuberculosis and Lung Disease. 2008; 12(4):447-452